10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________________________________________ 

FORM 10-Q 

____________________________________________________________________________________________

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______ 

Commission File Number: 001-37854 

____________________________________________________________________________________________ 

Ekso Bionics Holdings, Inc.

(Exact name of registrant as specified in its charter) 

____________________________________________________________________________________________

Nevada	99-0367049
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

 

101 Glacier Point, Suite A San Rafael, CA	94901
(Address of principal executive offices)	(Zip Code)

(510) 984-1761

(Registrant’s telephone number, including area code)

________________________________

(Former name, former address, and former fiscal year, if changed since last report)

____________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EKSO	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x     No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

The number of shares of registrant’s common stock outstanding as of November 1, 2022 was 13,142,418.

 Ekso Bionics Holdings, Inc.

Quarterly Report on Form 10-Q 

Table of Contents

  

		Page No.
	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	4
	Condensed Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021	4
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2022 and 2021 (unaudited)	5
	Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months ended September 30, 2022 and 2021 (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2022 and 2021 (unaudited)	8
	Notes to Condensed Consolidated Financial Statements (unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
Item 4.	Controls and Procedures	39
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 6.	Exhibits	41
	Signatures	42

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Ekso Bionics Holdings, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except par value)

 

	September 30, 2022		December 31, 2021
	(unaudited)		(Note 2)
Assets
Current assets:
Cash	$	29,180	$	40,406
Accounts receivable, net of allowances of $30 and $28, respectively	3,398		4,662
Inventories	3,508		2,242
Prepaid expenses and other current assets	668		485
Total current assets	36,754		47,795
Property and equipment, net	959		991
Right-of-use assets	1,374		216
Other assets	224		164
Total assets	$	39,311	$	49,166
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,387	$	3,107
Accrued liabilities	2,172		2,299
Deferred revenues, current	1,059		1,220
Note payable, current	1,996		—
Lease liabilities, current	244		229
Total current liabilities	7,858		6,855
Deferred revenues	1,032		1,475
Note payable, net	—		1,993
Lease liabilities	1,167		—
Warrant liabilities	539		1,550
Other non-current liabilities	101		74
Total liabilities	10,697		11,947
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at September 30, 2022 and December 31, 2021	—		—
Common stock, $0.001 par value; 141,429 shares authorized; 13,127 and 12,693 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	13		13
Additional paid-in capital	247,884		246,090
Accumulated other comprehensive income (loss)	1,486		(17)
Accumulated deficit	(220,769)		(208,867)
Total stockholders’ equity	28,614		37,219
Total liabilities and stockholders’ equity	$	39,311	$	49,166

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)

 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenue	$	3,329	$	3,049	$	9,361	$	7,170
Cost of revenue	1,643		1,242		4,825		2,836
Gross profit	1,686		1,807		4,536		4,334
Operating expenses:
Sales and marketing	1,742		1,685		5,212		5,265
Research and development	936		618		2,855		1,930
General and administrative	2,662		2,293		7,589		6,415
Total operating expenses	5,340		4,596		15,656		13,610
Loss from operations	(3,654)		(2,789)		(11,120)		(9,276)
Other (expense) income, net:
Interest expense	(34)		(24)		(90)		(77)
Gain on revaluation of warrant liabilities	112		1,125		1,011		2,011
Gain on forgiveness of note payable	—		—		—		1,099
Unrealized loss on foreign exchange	(732)		(268)		(1,704)		(640)
Other income (expense), net	4		(2)		1		(18)
Total other (expense) income, net	(650)		831		(782)		2,375
Net loss	$	(4,304)	$	(1,958)	$	(11,902)	$	(6,901)
Other comprehensive income	652		261		1,503		601
Comprehensive loss	$	(3,652)	$	(1,697)	$	(10,399)	$	(6,300)
Net loss per share applicable to common shareholders, basic	$	(0.33)	$	(0.15)	$	(0.92)	$	(0.57)
Net loss per share applicable to common shareholders, diluted	$	(0.33)	$	(0.17)	$	(0.92)	$	(0.62)
Weighted average number of shares outstanding, basic	13,071		12,661		12,896		12,029
Weighted average number of shares outstanding, diluted	13,071		12,710		12,896		12,133

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands)

(Unaudited)

	Convertible Preferred Stock			Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive (Loss) Income		Accumulated Deficit		Total Stockholders’  Equity
	Shares	Amount		Shares	Amount
Balance at December 31, 2021	—	$	—	12,693	$	13	$	246,090	$	(17)	$	(208,867)	$	37,219
Net loss	—	—		—	—		—		—		(4,620)		(4,620)
Issuance of common stock under:
Matching contribution to 401(k) plan	—	—		68	—		176		—		—		176
Equity incentive plan	—	—		83	—		—		—		—		—
Stock-based compensation expense	—	—		—	—		499		—		—		499
Foreign currency translation adjustments	—	—		—	—		—		212		—		212
Balance at March 31, 2022	—	$	—	12,844	$	13	$	246,765	$	195	$	(213,487)	$	33,486
Net loss	—	—		—	—		—		—		(2,978)		(2,978)
Issuance of common stock under:
Equity incentive plan	—	—		166	—		—		—		—		—
Stock-based compensation expense	—	—		—	—		582		—		—		582
Foreign currency translation adjustments	—	—		—	—		—		639		—		639
Balance at June 30, 2022	—	$	—	13,010	$	13	$	247,347	$	834	$	(216,465)	$	31,729
Net loss	—	—		—	—		—		—		(4,304)		(4,304)
Issuance of common stock under:
Equity incentive plan	—	—		117	—		—		—		—		—
Stock-based compensation expense	—	—		—	—		537		—		—		537
Foreign currency translation adjustments	—	—		—	—		—		652		—		652
Balance at September 30, 2022	—	$	—	13,127	$	13	$	247,884	$	1,486	$	(220,769)	$	28,614

Ekso Bionics Holdings, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands)

(Unaudited)

	Convertible Preferred Stock			Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive (Loss) Income		Accumulated Deficit		Total Stockholders’ Equity
	Shares	Amount		Shares	Amount
Balance at December 31, 2020	—	$	—	8,349	$	8	$	204,376	$	(847)	$	(199,103)	$	4,434
Net loss	—	—		—	—		—		—		(3,670)		(3,670)
Issuance of common stock under:
Equity financing, net	—	—		3,980	4		35,356		—		—		35,360
Exercise of warrants	—	—		300	1		3,877		—		—		3,878
Matching contribution to 401(k) plan	—	—		26	—		152		—		—		152
Stock-based compensation expense	—	—		—	—		356		—		—		356
Foreign currency translation adjustments	—	—		—	—		—		465		—		465
Balance at March 31, 2021	—	$	—	12,655	$	13	$	244,117	$	(382)	$	(202,773)	$	40,975
Net loss	—	—		—	—		—		—		(1,273)		(1,273)
Stock-based compensation expense	—	—		—	—		519		—		—		519
Foreign currency translation adjustments	—	—		—	—		—		(125)		—		(125)
Balance at June 30, 2021	—	$	—	12,655	$	13	$	244,636	$	(507)	$	(204,046)	$	40,096
Net loss	—	—		—	—		—		—		(1,958)		(1,958)
Issuance of common stock under:
Equity incentive plan	—	—		9	—		—		—		—		—
Stock-based compensation expense	—	—		—	—		663		—		—		663
Foreign currency translation adjustments	—	—		—	—		—		261		—		261
Balance at September 30, 2021	—	$	—	12,664	$	13	$	245,299	$	(246)	$	(206,004)	$	39,062

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2022		2021
Operating activities:
Net loss	$	(11,902)	$	(6,901)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	632		782
Changes in allowance for doubtful accounts	(11)		48
Gain on forgiveness of note payable	—		(1,099)
Gain on revaluation of warrant liabilities	(1,011)		(2,011)
Stock-based compensation expense	1,618		1,538
Common stock contribution to 401(k) plan	147		141
Unrealized loss on foreign currency transactions	1,704		640
Changes in operating assets and liabilities:
Accounts receivable	1,044		(10)
Inventories	(1,477)		(171)
Prepaid expenses and other assets, current and noncurrent	(277)		(251)
Accounts payable	(704)		(189)
Accrued, lease and other liabilities, current and noncurrent	(270)		(70)
Deferred revenues	(537)		(528)
Net cash used in operating activities	(11,044)		(8,081)
Investing activities:
Acquisition of property and equipment	(141)		(60)
Net cash used in investing activities	(141)		(60)
Financing activities:
Proceeds from issuance of common stock and warrants, net	—		37,295
Proceeds from exercise of warrants	—		1,417
Net cash provided by financing activities	—		38,712
Effect of exchange rate changes on cash	(41)		6
Net (decrease) increase in cash	(11,226)		30,577
Cash at beginning of period	40,406		12,862
Cash at end of period	$	29,180	$	43,439
Supplemental disclosure of cash flow activities
Cash paid for interest	$	88	$	69
Cash paid for income taxes	$	14	$	—
Supplemental disclosure of non-cash activities
Fair value of warrants issued upon equity financing	$	—	$	1,936
Reclassification of warrant liability to equity upon exercise of warrants	$	—	$	2,461
Transfer of inventory to property and equipment	$	192	$	387
Initial recognition of operating lease liabilities and right of use assets	$	1,459	$	—
Share issuance for common stock contribution to 401(k) plan	$	176	$	152

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

1.    Organization

Description of Business

Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and by persons with physical disabilities. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI"), to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol “EKSO”.

Liquidity and Capital Resources

As of September 30, 2022, the Company had an accumulated deficit of $220,769.  Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the nine months ended September 30, 2022, the Company used $11,044 of cash in its operations. Cash on hand as of September 30, 2022 was $29,180.

As described in Note 8, Notes payable, net, borrowings under the Company’s secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of September 30, 2022, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of September 30, 2022 is approximately $27,180. With this unrestricted cash balance, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.

2.    Basis of Presentation and Summary of Significant Accounting Policies and Estimates

Basis of Presentation and Consolidation

The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 24, 2022.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.

The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any future periods.

The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.

Reclassifications

During the nine months ended September 30, 2022, the Company reclassified the amortization of operating lease right-of-use assets in its condensed consolidated statements of cash flows. Amounts amortized related to operating lease right-of-use assets

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

have been reclassified to "Depreciation and amortization" from "Prepaid expenses and other assets, current and noncurrent" as applicable. Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects. These reclassifications did not affect changes in cash flow used in operating activities or net (decrease) in cash for the nine months ended September 30, 2021.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue, the valuation of warrants and employee equity awards, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.

Foreign Currency

The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.

Inventory

Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.

Leases

The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

Revenue Recognition

The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.

The Company exercised judgement to determine that a product returns reserve was not required as historical returns activity have not been material.

Going Concern

The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.

Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of September 30, 2022 and December 31, 2021. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon collecting receivables denominated in a foreign currency.

At September 30, 2022, the Company had two customers (13% and 12%) with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable, as compared with zero customers at December 31, 2021.

During the three months ended September 30, 2022, the Company had two customers with sales of 10% or more of the Company’s total revenue (20% and 14%), as compared with none in the three months ended September 30, 2021.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

During the nine months ended September 30, 2022, the Company had one customer with sales of 10% or more of the Company’s total revenue (14%), as compared with none in the nine months ended September 30, 2021.

Recent Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2022-02, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company beginning in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its condensed consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2024 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2020-06 to be material on its consolidated financial statements.

3.    Accumulated Other Comprehensive Income (Loss)

The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the nine months ended September 30, 2022 and 2021, is reflected in the table below net of tax:

	Nine Months Ended September 30,
	2022		2021
Balance at beginning of period	$	(17)	$	(847)
Net unrealized gain on foreign currency translation	1,503		601
Balance at end of period	$	1,486	$	(246)

4.    Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:

•Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.

The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:

	Total		Level 1		Level 2		Level 3
September 30, 2022
Liabilities
Warrant liabilities	$	539	$	—	$	—	$	539
December 31, 2021
Liabilities
Warrant liabilities	$	1,550	$	—	$	—	$	1,550

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2022, which were measured at fair value on a recurring basis:

	Warrant Liability
Balance at December 31, 2021	$	1,550
Gain on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings	(1,011)
Balance at September 30, 2022	$	539

Refer to Note 10. Capitalization and Equity Structure – Warrants for additional information regarding the valuation of warrants.

5.    Inventories

Inventories consisted of the following:

	September 30, 2022		December 31, 2021
Raw materials	$	2,845	$	2,061
Work in progress	373		145
Finished goods	290		36
Inventories	$	3,508	$	2,242

6.    Revenue

The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, the sale of support and maintenance contracts (Ekso Care), and the sale of accessories for the EksoNR. In 2021, the Company moved to a customer subscription sales model and away from a rental sales model. Under the rental sales model, the Company offered customers a short-term rental arrangement of its products to help bridge to a capital purchase since customers typically have challenges in obtaining approvals for capital expenditures. Subscription sales arrangements, however, bypass the customer capital purchase process, are intended to renew annually, and provide a long-term revenue stream.

Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements. The separately priced Ekso Care contracts range from 12 to 48 months. The Company receives payment at the

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

inception of the contract and recognizes revenue evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the initial contract term, typically over 12 to 24 months.

The Company’s industrial device segment (EksoWorks) revenue is generated through the sale of the upper body exoskeletons (EksoVest and the EVO) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility.

At the end of the second quarter of 2022, the Company ceased commercialization of the EksoZeroG support arm and related products and accessories. The Company may continue to sell parts and accessories to existing EksoZeroG customers to deplete its current stock of EksoZeroG inventories, however, the Company does not expect any future revenues derived from the sale of the EksoZeroG product line to have a material contribution to EksoWorks segment revenues. Refer to Note 13 Commitment and Contingencies for further information regarding commitments and obligations related to the EksoZeroG product line.

Deferred Revenue

For the sale of its products, the Company recognizes revenue upon the transfer of control of products to its customers, typically upon shipment from its facilities. For the subscription of its products, the Company generally recognizes revenue over the subscription term commencing upon the completion of customer training. For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.

Deferred revenue is comprised mainly of unearned revenue related to service agreement contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.

Deferred revenue consisted of the following:

	September 30, 2022		December 31, 2021
Deferred extended maintenance and support	$	2,056	$	2,349
Deferred royalties	—		280
Customer advances	35		66
Total deferred revenues	2,091		2,695
Less current portion	(1,059)		(1,220)
Deferred revenues, non-current	$	1,032	$	1,475

Deferred revenue activity consisted of the following for the nine months ended September 30, 2022:

Beginning balance	$	2,695
Deferral of revenue	1,014
Recognition of deferred revenue	(1,618)
Ending balance	$	2,091

As of September 30, 2022, the Company’s deferred revenue was $2,091. The Company expects to recognize approximately $375 of the deferred revenue during the remainder of 2022, $897 in 2023, and $819 thereafter.

In addition to deferred revenue, the Company has a non-cancellable backlog of $2,527 related to its contracts for subscription units with its customers. These subscription contracts typically have 12 to 24 month terms, and subscription income is recognized on a straight-line basis over the term of the contract.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

In the nine months ended September 30, 2022, the Company recognized revenue of $280 related to a $300 upfront royalty payment associated with a license and distribution agreement that expired. The unrecognized royalty balance of $280 was included in deferred revenue as of December 31, 2021.

As of September 30, 2022 and December 31, 2021, total accounts receivable, net of allowance for doubtful accounts, were $3,536 and $4,824, respectively, and are included in accounts receivable, net and other assets on the Company’s condensed consolidated balance sheets.

The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source for the three months ended September 30, 2022:

	EksoHealth		EksoWorks		Total
Device revenue	$	2,338	$	72	$	2,410
Service and support	484		—		484
Subscriptions	237		14		251
Parts and other	165		19		184
	$	3,224	$	105	$	3,329

The following table disaggregates the Company’s revenue by major source for the nine months ended September 30, 2022:

	EksoHealth		EksoWorks		Total
Device revenue	$	5,670	$	544	$	6,214
Service and support	1,440		—		1,440
Subscriptions	678		134		812
Parts and other	438		350		788
Collaborative arrangements	107		—		107
	$	8,333	$	1,028	$	9,361

The following table disaggregates the Company’s revenue by major source for the three months ended September 30, 2021:

	EksoHealth		EksoWorks		Total
Device revenue	$	1,791	$	240	$	2,031
Service and support	477		—		477
Rentals and subscriptions	173		66		239
Parts and other	233		27		260
Collaborative arrangements	42		—		42
	$	2,716	$	333	$	3,049

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

The following table disaggregates the Company’s revenue by major source for the nine months ended September 30, 2021:

	EksoHealth		EksoWorks		Total
Device revenue	$	3,900	$	625	$	4,525
Service and support	1,412		—		1,412
Rentals and subscriptions	510		188		698
Parts and other	427		51		478
Collaborative arrangements	57		—		57
	$	6,306	$	864	$	7,170

7.    Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2022		December 31, 2021
Salaries, benefits and related expenses	$	1,822	$	2,015
Device warranty	224		195
Other	126		89
Total	$	2,172	$	2,299

The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three and nine months ended September 30, 2022 is as follows:

	Three Months Ended		Nine Months Ended
	September 30, 2022		September 30, 2022
Balance at beginning of period	$	275	$	270
Additions for estimated future costs	124		256
Incurred costs	(74)		(201)
Balance at end of period	$	325	$	325
			Balance as of September 30, 2022
Current portion			$	224
Long-term portion			101
Total			$	325

8.    Notes Payable, net

PWB Term Loan

In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its “prime rate” then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.

The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of September 30, 2022. On September 30, 2022, with cash on hand of $29,180, the Company was compliant with this liquidity covenant and all other covenants.

The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 6.45% and 5.37% for the three and nine months ended September 30, 2022, respectively. The debt issuance costs are amortized to interest expense using the effective interest method over the life of the loan.

The following table presents scheduled principal payments of the Company’s PWB term loan as of September 30, 2022:

Period	Amount
Remainder of 2022	$	—
2023	2,000
Total principal payments	2,000
Less debt discount and issuance cost	4
Note payable, net	$	1,996
Current portion	$	1,996
Long-term portion	—
Note payable, net	$	1,996

Paycheck Protection Program Loan

On April 20, 2020, the Company received an unsecured loan (the "PPP Loan") in the principal amount of $1,086 under the Paycheck Protection Program (the “PPP”) administered by the U.S. Small Business Administration (the "SBA"), pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan bore interest at 1.00% per annum, and matured two years after the date of initial disbursement. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, (the "PPP Flexibility Act"), which was enacted on June 5, 2020. The PPP Loan was used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments and interest payments on other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company could apply for and be granted forgiveness for all or a portion of the PPP Loan, with such forgiveness to be determined, subject to limitations (including whether employees of the Company have been terminated and not re-hired by a certain date), based on the use of the PPP Loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness were also subject to further requirements in regulations and guidelines adopted by the SBA.

On June 28, 2021, the Company received notification from the SBA that the Company’s forgiveness application for the PPP Loan and accrued interest, totaling $1,099, was approved in full, and the Company had no further obligations related to the PPP Loan. Accordingly, the Company recorded a gain on the forgiveness of the PPP Loan as gain on forgiveness of note payable on the condensed consolidated statement of operations during the nine months ended September 30, 2021.

9.    Lease Obligations

The Company maintained a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California (the "Richmond Lease") which expired at the end of May 2022. The Company continued to maintain its tenancy at this location until the end of August 2022. Pursuant to the terms of the original lease agreement, the Company incurred monthly

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

expenses equal to the most recent monthly lease payment under the now expired lease agreement and common area maintenance costs plus a 25% mark-up.

In July 2022, the Company entered into an operating lease agreement for its new headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") expiring in October 2026 with the option to renew for an additional three-year period at the prevailing market rate at the time of extension. At the end of August 2022, the Company relocated to its new headquarters and manufacturing facility in San Rafael.

The Company has determined that the new San Rafael Lease constitutes an operating lease under ASC 842 and estimates the lease term as July 2022 through October 2026. The option to extend for a three-year period lacks significant economic incentives and disincentives, which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for the San Rafael Lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company previously maintained a five-year operating lease agreement for its European operations office in Hamburg, Germany, which was originally set to expire in July 2022. In February 2022, the Company executed a new lease agreement with the same landlord for a replacement office in Hamburg, Germany commencing May 1, 2022 and expiring June 30, 2025 with an option to renew for one five-year period. Upon the early termination of the previous lease agreement, it was agreed between the landlord and the Company that access to the previously leased office space would be revoked and the Company would be relieved of its payment obligations for the final two months of the lease term. Consequently, the Company removed the right of use asset and lease liability, $15 and $16 respectively, recorded in its condensed consolidated financial statements related to the original Hamburg tenancy.

The Company has determined that the new Hamburg lease agreement constitutes a lease under ASC 842 and estimates the lease term as May 2022 through June 2025. The option to extend for a five-year period lacks significant economic incentives and disincentives which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company’s future lease payments as of September 30, 2022, which are presented as Lease liabilities, current and Lease liabilities on the Company’s condensed consolidated balance sheets are as follows:

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

Periods	Operating Leases
Remainder of 2022	$	13
2023	403
2024	415
2025	399
2026	349
Total lease payments	1,579
Less: imputed interest	(168)
Present value of lease liabilities	$	1,411
Weighted-average remaining lease term (in years)	3.95
Weighted-average discount rate	5.4		%

Lease expense under the Company’s operating leases was $189 and $130 for the three months ended September 30, 2022 and 2021, respectively, and $455 and $395 for the nine months ended September 30, 2022 and 2021, respectively.

10.    Capitalization and Equity Structure

Summary

The Company’s authorized capital stock at September 30, 2022 and December 31, 2021 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. As of September 30, 2022 and December 31, 2021, there were 13,127 and 12,693, respectively, shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

Common Stock

February 2021 Offering

In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for a public price of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering"). The Company received net proceeds of $36,504 from the February 2021 Offering after deducting underwriting discounts, commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued, to certain designees of Wainwright, five-year warrants (the “2021 Warrants”) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering, or 273 shares, at an exercise price of $12.81 per share.

At the Market Offering

In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. The Company may offer and sell shares having an aggregate offering price of up to $7,500 under the registration statement and prospectus supplement filed with the SEC related to such offering. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share. The Company did not sell any shares under the ATM agreement during the three and nine months ended September 30, 2022. During the nine months ended September 30, 2021, the Company sold 78 shares of common stock at an average price of $10.72 for proceeds of $791, net of commissions and issuance costs. The Company did not sell any shares under the ATM Agreement during the three months ended September 30, 2021. As of September 30, 2022, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

Warrants

Warrants outstanding as of September 30, 2022 and December 31, 2021 were as follows:  

Source	Exercise Price		Term (Years)	December 31, 2021	Issued	Exercised	September 30, 2022
2021 Warrants	$	12.81	5	273	—	—	273
June 2020 Investor Warrants	$	5.18	5.5	127	—	—	127
June 2020 Placement Agent Warrants	$	5.64	5	39	—	—	39
December 2019 Warrants	$	8.10	5	556	—	—	556
December 2019 Placement Agent Warrants	$	8.44	5	52	—	—	52
May 2019 Warrants	$	3.52	5	193	—	—	193
				1,240	—	—	1,240

During the nine months ended September 30, 2021, the Company received net proceeds of $1,417 from the exercise of 358 warrants and issued 300 shares of common stock, respectively, as a result of those exercises. No warrants were exercised during the nine months ended September 30, 2022.

2021 Warrants

In February 2021, the Company issued the 2021 Warrants, exercisable for up to 273 shares of the Company’s common stock at an exercise price of $12.81 per share. The 2021 Warrants were exercisable immediately, and will expire five years from the date of issuance, or on February 11, 2026.

In addition, the 2021 Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its 2021 Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the 2021 Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the 2021 Warrants. The 2021 Warrants will be automatically exercised on a cashless basis on their expiration date. The 2021 Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants.

The 2021 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the 2021 Warrants, the Company or any successor entity will, at the option of a holder of a 2021 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s 2021 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s 2021 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the 2021 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the 2021 Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the 2021 Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	12.81		$	12.81
Risk-free interest rate	4.22		%	1.13		%
Expected term (years)	3.36			4.11
Volatility of stock	97.7		%	98.3		%

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

June 2020 Investor Warrants

In June 2020, the Company issued warrants (the "June 2020 Investor Warrants"), exercisable for up to 874 shares of the Company’s common stock at an exercise price of $5.18 per share. The June 2020 Investor Warrants were immediately exercisable, and will expire five and one-half years from the date of issuance, or on December 10, 2025.

In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.

The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the nine months ended September 30, 2022 and 2021, no shares and 270 shares of the June 2020 Investor Warrants were exercised, respectively.

The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the June 2020 Investor Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	5.18		$	5.18
Risk-free interest rate	4.23		%	1.11		%
Expected term (years)	3.19			3.94
Volatility of stock	99.5		%	103.9		%

June 2020 Placement Agent Warrants

In June 2020, the Company issued warrants (the "June 2020 Placement Agent Warrants"), exercisable for up to 122 shares of the Company’s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $5.64, subject to adjustment in certain circumstances, and will expire on June 7, 2025. During the nine months ended September 30, 2022 and 2021, no shares and 83 shares of the June 2020 Placement Agent Warrants were exercised, respectively.

Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	5.64		$	5.64
Risk-free interest rate	4.19		%	1.03		%
Expected term (years)	2.69			3.44
Volatility of stock	101.4		%	100		%

December 2019 Warrants

In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering"), the Company issued warrants (the "December 2019 Warrants") to purchase 556 shares of common stock. The December 2019 Warrants are currently exercisable, have an exercise price of $8.10 per share, and will expire five years from the date they initially became exercisable, or on June 21, 2025.

The December 2019 Warrants also contain a cashless exercise provision and could require cash payments in the event of a failure to timely deliver securities or in the event of insufficient authorized shares. The December 2019 Warrants will be automatically exercised on a cashless basis on their expiration date. The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s December 2019 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	8.10		$	8.10
Risk-free interest rate	4.19		%	1.04		%
Expected term (years)	2.72			3.47
Volatility of stock	101.3		%	99.7		%

December 2019 Placement Agent Warrants

In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase 52 shares of the Company’s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $8.44, subject to adjustment in certain circumstances, and will expire on December 18, 2025.

The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	8.44		$	8.44
Risk-free interest rate	4.09		%	0.96		%
Expected term (years)	2.22			2.97
Volatility of stock	72.9		%	102.9		%

Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.

May 2019 Warrants

In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued the warrants (the "May 2019 Warrants") to purchase 444 shares of common stock. The May 2019 Warrants are currently exercisable, have a current exercise price of $3.52 per share, and will expire five years from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company’s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $3.52 per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $4.51 per share, (y) the lowest exercise price of the June 2020 Investor Warrants, or $5.18, and (z) the lowest one-day volume-weighted average price of the Company’s Common Stock on the Nasdaq Capital Market as measured each day during the five trading day period starting on June 8, 2020, rounded to the nearest share, or $3.52. During the nine months ended September 30, 2022 and 2021, no shares and 5 shares of the May 2019 Warrants were exercised, respectively.

In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder’s warrant, elect to exercise the warrant at such variable price.

The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder’s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. Because of the price protection feature contained in the May 2019 Warrants, the Company uses a combination of the Black-Scholes Model and the Lattice Model to estimate the fair value of the warrants at each reporting period. The following assumptions were used in the Black-Scholes Model in combination with the Lattice Model to measure the fair value of the May 2019 Warrants:

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

	September 30, 2022			December 31, 2021
Share price	$	1.56		$	2.65
Conversion price	$	3.52		$	3.52
Risk-free interest rate	4.16		%	0.83		%
Expected term (years)	1.6			2.4
Volatility of stock	73.7		%	109.1		%

Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.

11.    Stock-based Compensation

Shares available to grant

On June 9, 2022, the Company held its 2022 annual meeting of stockholders and ratified an amendment to the Company's Amended and Restated 2014 Equity Incentive Plan to increase the total number of shares of common stock authorized for issuance by 550 shares. As of September 30, 2022, the total shares authorized for grant under the 2014 Plan was 2,524, of which 654 were available for future grants.

Stock Options

The following table summarizes information about the Company’s stock options outstanding as of September 30, 2022, and activity during the nine months then ended:

	Stock Awards	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Balance as of December 31, 2021	491	$	32.53
Options forfeited	(51)	12.66
Options cancelled	(169)	29.82
Balance as of September 30, 2022	271	$	37.97	5.51	$	—
Vested and expected to vest at September 30, 2022	271	$	37.97	5.51	$	—
Exercisable as of September 30, 2022	259	$	39.24	5.44	$	—

As of September 30, 2022, total unrecognized compensation cost related to unvested stock options was $79. This amount is expected to be recognized as stock-based compensation expense in the Company’s condensed consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 1.02 years.

There were no stock options awarded for the three and nine months ended September 30, 2022 or the three and nine months ended September 30, 2021.

Restricted Stock Units

The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employee members of the Board. Each RSU and PSU represents the right to receive one share of the Company’s common stock upon vesting and subsequent settlement. PSUs vest upon achievement of performance targets based on the Company's annual operating plan.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

The fair values of RSUs and PSUs are determined based on the closing price of the Company’s common stock on the date of grant.

Combined RSU and PSU activity for the nine months ended September 30, 2022 is summarized below:

	Number of Shares	Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2021	655	$	5.63
Granted	896	2.05
Vested	(409)	4.65
Forfeited	(193)	5.52
Unvested at September 30, 2022	949	$	2.72

As of September 30, 2022, $2,051 of total unrecognized compensation expense related to unvested RSUs and PSUs was expected to be recognized over a weighted average period of 1.61 years.

Compensation Expense

Total stock-based compensation expense related to options, RSUs and PSUs granted to employees and non-employee members of the board of directors is included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Sales and marketing	$	61	$	119	$	202	$	310
Research and development	90		74		273		184
General and administrative	386		470		1,143		1,045
	$	537	$	663	$	1,618	$	1,539

401(k) Plan Share Match

During the nine months ended September 30, 2022 and 2021, the Company issued 68 and 26 shares of common stock with a fair value of $176 and $152, to eligible employees’ deferral accounts for the 401(k) Plan matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the fiscal years ended December 31, 2021 and 2020, respectively.

The expense related to the accrual for the 401(k) plan share matching was $147 and $141 for the nine months ended September 30, 2022 and 2021, respectively.

12.    Income Taxes

There were no material changes to the unrecognized tax benefits in the nine months ended September 30, 2022, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years remain open to tax examination.

13.    Commitments and Contingencies

Material Contracts

The Company enters various license, research collaboration and development agreements, which provide for payments to the Company primarily for technology transfer and license fees, and royalty payments on sales.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

The Company has two license agreements with the Regents of the University of California to maintain exclusive rights to certain patents. The Company is required to pay 1% of net sales of licensed medical devices sold to entities other than the U.S. government. In addition, the Company is required to pay 21% of consideration collected from any sub-licensee for the grant of the sub-license.

The Company entered into a research and development collaboration agreement in December 2021 with a party that develops technologies having utility in robotic exoskeletons from research and development activities associated with a specific set of government funded research projects. Since January 2022, the Company has assisted with research and development activities in exchange for access to a worldwide, royalty free, transferable, sublicensable, exclusive license to design and market products that use or incorporate the jointly-developed technology within Ekso’s target market segments.

Under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which granted the Company an exclusive license with respect to the technology and patent rights for certain fields of use, the Company was required to pay the developer a single-digit royalty on net receipts, subject to a $50 annual minimum royalty requirement. At the end of the second quarter of 2022, the Company ceased commercialization of the EksoZeroG support arm and is no longer required to pay the developer any further royalties.

Purchase Obligations

The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Due to a variety of factors, including the COVID-19 pandemic, various materials the Company used to manufacture its products are currently experiencing shortages and supply chain disruptions. Electronic components in general, semiconductor chips, battery cells, metals and plastics, all of which are used in the Company's products, are also in shorter supply compared to prior periods, and the Company is also experiencing longer lead times for manufacturing services such as machining and tool making and increased pricing. Numerous factors, such as the ongoing pandemic or further trade tensions between the U.S. and China, may prolong or deepen these challenges.

The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $3,203 as of September 30, 2022, which are expected to be paid within one year, and $1,446 as of December 31, 2021. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.

The Company has operating lease commitments totaling $1,579 payable over 49 months related to the San Rafael and Hamburg leases disclosed in Note 9. Lease Obligations.

Contingencies

In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s condensed consolidated financial statements.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

14.    Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(4,304)	$	(1,958)	$	(11,902)	$	(6,901)
Adjustment for gain on revaluation of warrant liabilities	—		(158)		—		(643)
Net loss applicable to common stockholders, diluted	$	(4,304)	$	(2,116)	$	(11,902)	$	(7,544)
Denominator:
Weighted-average number of shares, basic	13,071		12,661		12,896		12,029
Effect of dilutive warrants	—		49		—		104
Weighted-average number of shares, diluted	13,071		12,710		12,896		12,133
Net loss per share, basic	$	(0.33)	$	(0.15)	$	(0.92)	$	(0.57)
Net loss per share, diluted	$	(0.33)	$	(0.17)	$	(0.92)	$	(0.62)

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Options to purchase common stock	271	499	271	499
Restricted stock units	949	596	949	596
Warrants for common stock	1,240	1,047	1,240	881
Total common stock equivalents	2,460	2,142	2,460	1,976

15.    Segment Disclosures

The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.

The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

Segment reporting information is as follows:

	EksoHealth		EksoWorks		Total
Three months ended September 30, 2022
Revenue	$	3,224	$	105	$	3,329
Cost of revenue	1,524		119		1,643
Gross profit	$	1,700	$	(14)	$	1,686
Three months ended September 30, 2021
Revenue	$	2,716	$	333	$	3,049
Cost of revenue	1,044		198		1,242
Gross profit	$	1,672	$	135	$	1,807

	EksoHealth		EksoWorks		Total
Nine months ended September 30, 2022
Revenue	$	8,333	$	1,028	$	9,361
Cost of revenue	4,170		655		4,825
Gross profit	$	4,163	$	373	$	4,536
Nine months ended September 30, 2021
Revenue	$	6,306	$	864	$	7,170
Cost of revenue	2,326		510		2,836
Gross profit	$	3,980	$	354	$	4,334

Ekso Bionics Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

($ and share amounts in thousands, except per share amounts)

(Unaudited)

The Company operates in the following regions: (1) Americas, (2) Europe, the Middle East, and Africa (EMEA), and (3) Asia Pacific (APAC). Individual countries with revenue greater than 10% of total revenue for the three and nine months ended September 30, 2022 and 2021 are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Americas
United States	$	1,475	$	1,777	$	4,889	$	3,914
Other	73		25		249		105
Americas	1,548		1,802		5,138		4,019
EMEA
Germany	237		313		487		845
Romania	449		121		449		121
Other	372		394		1,472		1,356
EMEA	1,058		828		2,408		2,322
APAC
Indonesia	668		—		668		—
Other	55		419		1,147		829
APAC	723		419		1,815		829
Total Revenue	$	3,329	$	3,049	$	9,361	$	7,170

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

In this Quarterly Report, the “Company”, “we”, “its” and “our” refers to Ekso Bionics Holdings, Inc. and its wholly-owned subsidiaries. The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this “Quarterly Report”) and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which is incorporated herein by reference (the “Annual Report”).

This Quarterly Report contains forward-looking statements. These forward-looking statements include statements other than statements of historical facts contained or incorporated by reference in this Quarterly Report, including statements regarding (i) the plans and objectives of management for future operations, including those relating to the design, development and commercialization of exoskeleton products for humans, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC, (iv) our beliefs regarding the potential for commercial opportunities for exoskeleton technology in general and our exoskeleton products in particular, (v) our beliefs regarding potential clinical and other health benefits of our medical devices, and (vi) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv) or (v) above. The words “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and similar expressions (including the negative of any of the foregoing) are intended to identify forward-looking statements.

The following factors, among others, including those described in the section titled “Risk Factors” included in our Annual Report, as updated and supplemented in this Quarterly Report under the heading “Part II – Item 1A. Risk Factors,” could cause our future results to differ materially from those expressed in the forward-looking information:

•our ability to obtain adequate financing to fund operations and to develop or enhance our technology;

•our ability to obtain or maintain regulatory approval to market our medical devices;

•our ability to complete clinical trials on a timely basis and that completed clinical trials will be sufficient to support commercialization of our products;

•the anticipated timing, cost and progress of the development and commercialization of new products or services, and improvements to our existing products, and related impacts on our profitability and cash position;

•our ability to effectively market and sell our products and expand our business, both in unit sales and product diversification;

•our ability to achieve broad customer adoption of our products and services;

•existing or increased competition;

•rapid changes in technological solutions available to our markets;

•volatility with our business, including long and variable sales cycles, which could have a negative impact on our results of operations for any given quarter;

•changes to our domestic or international sales and operations;

•our ability to obtain or maintain patent protection for our intellectual property;

•the scope, validity and enforceability of our and third-party intellectual property rights;

•significant government regulation of medical devices and the healthcare industry;

•our ability to receive regulatory clearance from certain government authorities, including any conditions, limitations or restrictions placed on such approvals;

•our customers’ ability to get third-party reimbursement for our products and services associated with them;

•the potential for our products to be subject to voluntary or involuntary recall;

•our product liability insurance may not adequately cover potential claims;

•warrant claims and our accelerated maintenance program results in additional operating costs to us;

•our failure to implement our business plan or strategies;

•our ability to successfully consummate acquisitions on acceptable terms and to integrate any such acquisitions;

•our early termination of leases, difficulty filling vacancies or negotiating improved lease terms;

•our ability to retain or attract key employees;

•scope, scale and duration of the impact of outbreaks of a pandemic disease, such as COVID-19 (coronavirus);

•stock volatility or illiquidity;

•our ability to maintain adequate internal controls over financial reporting;

•the impacts of foreign currency price fluctuations; and

•overall economic and market conditions.

Although we believe that the assumptions underlying the forward-looking statements and forward-looking information contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, such statements and information included in this Quarterly Report may not prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements and forward-looking information included herein, the inclusion of such statements and information should not be regarded as a representation by us or any other person that the results or conditions described in such statements and information or that our objectives and plans will be achieved. Such forward-looking statements speak only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

Our Business

We design, develop, and market exoskeleton products that augment human strength, endurance and mobility. Our exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and by persons with physical disabilities. We have sold or leased devices that (i) enable individuals with neurological conditions affecting gait, including ABI, SCI and MS, to rehabilitate, and in some cases, to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods.

We believe that the commercial opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements have become ubiquitous in peoples’ everyday lives. Supported by an industry leading intellectual property portfolio, we believe that we have learned how to integrate these existing technologies and wrap the result around a human being efficiently, elegantly and safely. We further believe this endeavor is achievable across a broad spectrum of applications, from persons with lower limb paralysis to able-bodied users.

EksoHealth

EksoHealth is our business unit focused on developing and marketing exoskeletons for medical applications.

Our leading product in EksoHealth, the EksoNR, is a robotic exoskeleton used to provide physical therapy for patients with lower extremity impairment. EksoNR includes unique features designed specifically to assist physical therapists and other clinicians to teach patients to walk again after suffering a neurological impairment. Typical conditions that can be treated with the assistance of EksoNR include ABIs, such as stroke and traumatic brain injuries, as well as SCIs, MS, and others. The benefits of EksoNR rehabilitation can include earlier mobilization of patients, longer and more intense rehab sessions, and increased quality of sessions as compared to alternative therapies. EksoNR is typically used in clinical settings, most commonly at inpatient rehab facilities and stroke centers.

EksoUE, our exoskeleton device purposed for upper-extremity medical applications, is a wearable upper body exoskeleton used for rehabilitation. EksoUE is designed to assist patients with a broad range of upper extremity impairments and aims to provide them with a wider active range of motion and increased endurance for rehabilitation sessions of higher intensity.

EksoWorks

EksoWorks is our business unit focused on developing, marketing, and selling exoskeletons and other assistive tools for industrial applications. Target users for these devices are generally able-bodied, and, as such, the technologies are primarily employed to reduce worker fatigue. The benefits of fatigue reduction can include reduced rates of injuries, higher productivity, increased worker morale, and lower employee turnover. EksoWorks products are primarily sold to companies deploying the technologies for use directly in their operations.

Our wearable exoskeleton products in EksoWorks include EksoVest and the new EVO, both of which are designed to support the weight of a worker’s arms and tools during overhead applications, reducing the fatigue associated with working at or above shoulder height for extended periods. These products are currently targeted at end users in the aerospace, automotive, manufacturing, and construction trades.

Prior to ceasing commercialization of the EksoZeroG support arm and related products and accessories, at the end of the second quarter of 2022, we manufactured and sold our EksoZeroG tool holder, which could mount on an aerial lift platform or

scaffolding. Refer to Note 6. Revenue Recognition in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.

Third Quarter 2022 Highlights

•Booked a total of 33 EksoNR units in the third quarter of 2022

•Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9% year-over-year

•Strong cash position of $29.2 million as of September 30, 2022

Economic and Industry Trends

Our revenue is highly dependent on market demand for our exoskeleton products. This market demand is influenced by many factors including the level of awareness of robotic exoskeleton rehabilitation among the rehabilitation clinics with significant ABI and SCI populations, the imperatives among construction and manufacturing companies to drive adoption of improved safety and health practices, as well as conditions relating to overall economic growth and general business activity. Difficult and challenging economic conditions, including growing supply chain issues amidst an increasingly inflationary environment, could lead to increased price-based competition. In particular, the effects of such increasing price-based competition may have an especially significant impact on certain products that we offer, including the EksoNR, which have a lengthy sale and purchase order cycle because they are major capital expenditure items and generally require the approval of senior management at purchasing institutions. Furthermore, our business includes operations in the Americas, EMEA and APAC, so we are affected by demand for our products in those regions, as well as the strengthening or weakening of local currencies relative to the U.S. Dollar.

The COVID-19 pandemic and related public health measures have also materially affected how we and our customers are operating our businesses, and have materially affected our operating results, as demand for our exoskeleton products decreased as many inpatient rehabilitation facilities temporarily shifted priorities and delayed capital expenditures. While the duration and extent to which this will impact our future results remain uncertain, we have seen certain recovery in the demand for our exoskeleton products following the gradual reopening and recovery of the broader global economy, and we believe the clinical need for our products has not diminished, as evidenced by clinical data showing the increased prevalence of strokes during the pandemic. Although concerns about the emergence of new, more infectious variants of the coronavirus remain, we have gradually resumed in-person engagements in addition to virtual meetings with our current and prospective customers through conferences, training events and educational demos to offer our support and showcase the value of our Ekso devices. Further, now that our clinical team is fully vaccinated and are active onsite at U.S. rehab centers, we expect to see an uptick in live in-person interactions going forward. Although market uncertainties related to the pandemic make it difficult for us to project the full impact on our business and customers, we believe that we are well-positioned to serve our customers when business conditions begin to normalize.

Throughout the pandemic, our top priority has been to protect the health and safety of our employees and our consumers. Employees who are essential to the daily operations are required to work in our facilities where enhanced personal protective equipment is in place. In addition, we have a hybrid work from home and office policy for our employees whose jobs can be performed outside of the office.

Management continues to actively monitor the global situation, including the geopolitical instability arising out of military conflict and escalating tensions between Russia and Ukraine, and its effects on our financial position and operations.

Management Changes

On January 14, 2022, Jack Peurach, our former President and Chief Executive Officer, notified us of his intention to resign as an officer and member of the Board of Directors of the Company to pursue other endeavors. On January 20, 2022, our Board and Mr. Peurach reached an understanding regarding his decision to leave the Company and entered into an Executive Separation and Release Agreement pursuant to which Mr. Peurach’s last day of service as the President, Chief Executive Officer and as a member of the Company’s Board was January 21, 2022.

In addition, our Board of Directors appointed Steven Sherman, who currently serves and previously had served as the Chairman of our Board, to become Chief Executive Officer of the Company effective January 22, 2022. Mr. Sherman continues to serve as the Chairman of the Board of the Company, and Board member Stanley Stern has been designated the Board’s lead

independent director. Furthermore, our Board of Directors appointed Scott Davis to become President and Chief Operating Officer effective January 22, 2022.

On March 4, 2022, William Shaw, our former Chief Commercial Officer, notified our Board of Directors of his intention to resign as Chief Commercial Officer of the Company effective March 11, 2022 in connection with his retention as an employee at another company.

On May 23, 2022, John F. Glenn our former Chief Financial Officer, notified the Company of his decision to resign from his position as the Company’s Chief Financial Officer, effective June 17, 2022, in connection with his retention as an employee at another public company. Mr. Glenn’s resignation is not the result of any dispute or disagreement with the Company including any matters relating to the Company’s accounting practices or financial reporting. On May 25, 2022, our board of directors approved the appointment of Jerome Wong as Interim Chief Financial Officer, effective upon Mr. Glenn’s departure. Mr. Wong was approved by our board of directors as Chief Financial Officer, Corporate Secretary and Principal Financial Officer on October 26, 2022, after serving as Interim Chief Financial Officer from May 25, 2022 to October 25, 2022.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Our estimates form the basis for our judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Our most critical accounting estimates include:

•the standalone selling prices used to allocate the contract consideration to the individual performance obligations in our device sales arrangements, which impacts revenue recognition;

•the unobservable inputs and assumptions used by management in estimating the fair value of our warrant liabilities, which impacts net income or loss;

•the valuation of inventory, which impacts gross profit margins; and

•the estimates made regarding the recoverability of our net deferred tax asset, which impacts our financial condition.

Standalone Selling Prices

Our device sales arrangements contain multiple products and services, most often including the device(s) and service, both of which we have identified as distinct performance obligations. Revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling prices considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and gross margin targets. Changes in the relative standalone selling price between devices and service can have an impact on how transaction prices are allocated between revenue and deferred revenue.

Warrant Liabilities

We use the Black-Scholes option-pricing model to value our warrant liabilities at each reporting period, which requires the input of highly subjective assumptions, most notably the estimated volatility of our common stock over the expected term. We use our historical common stock volatility to estimate expected volatility over the warrant terms. Management must also make uncertain estimates regarding the likelihood and timing of certain future events for application of the Lattice Model for the valuation of certain warrants. Changes in these assumptions could have potential material impacts on the estimated fair value of warrant liabilities. During the three months ended September 30, 2022, management made no changes to its estimates regarding the likelihood of future events, but revised its estimates regarding the timing of future events. We do not believe the revision resulted in a material impact to the estimated fair value of warrant liabilities measured using the Lattice Model.

Inventory Valuation

Inventory is stated at the lower of cost or net realizable value. Cost is computed using the standard cost method which approximates actual cost on a first-in, first-out basis. The cost basis of our inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which could have a material adverse effect on the results of our operations.

Deferred Tax Asset

We estimate a valuation allowance in consideration of the realizability of our net deferred tax assets, primarily based on our assessment of the timing, likelihood and amounts of potential future income during which such items become deductible. It is inherently difficult and subjective to estimate such amounts, as we must determine the probability of various possible outcomes and estimate future amounts. Management does not believe it is more likely than not that we will generate future income in a timeframe and amount sufficient to realize our net deferred tax assets. Changes in management's estimate of future income in the timeframe during which the temporary differences and carryforwards comprising our deferred tax assets become deductible could result in a material impact to our financial position including the recognition of a net deferred tax asset.

Accounting Policies

An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimate that are reasonably likely to occur, could materially impact the condensed consolidated financial statements. We believe that our critical accounting policies reflect the more significant estimates and assumptions used in the preparation of the condensed consolidated financial statements. Refer to Note. 2 Basis of Presentation and Summary of Significant Accounting Policies and Estimates in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Results of Operations

The following table presents our results of operations for the three months ended September 30, 2022 and 2021 (in thousands, except percentages):

	Three Months Ended September 30,
	2022			2021			Change		% Change
Revenue	$	3,329		$	3,049		$	280	9	%
Cost of revenue	1,643			1,242			401		32	%
Gross profit	1,686			1,807			(121)		(7)	%
Gross profit %	51		%	59		%
Operating expenses:
Sales and marketing	1,742			1,685			57		3	%
Research and development	936			618			318		51	%
General and administrative	2,662			2,293			369		16	%
Total operating expenses	5,340			4,596			744		16	%
Loss from operations	(3,654)			(2,789)			(865)		31	%
Other (expense) income, net:
Interest expense	(34)			(24)			(10)		42	%
Gain on revaluation of warrant liabilities	112			1,125			(1,013)		n/m(1)
Unrealized loss on foreign exchange	(732)			(268)			(464)		n/m(1)
Other income (expense), net	4			(2)			6		n/m(1)
Total other (expense) income, net	(650)			831			(1,481)		(178)	%
Net loss	$	(4,304)		$	(1,958)		$	(2,346)	120	%

(1)Not Meaningful

Revenue

Revenue increased $0.3 million, or 9%, for the three months ended September 30, 2022, compared to the same period of 2021. Revenue in the third quarter of 2022 included approximately $3.2 million in EksoHealth revenue and approximately $0.1 million in EksoWorks revenue.

EksoHealth revenue increased approximately $0.5 million for the three months ended September 30, 2022, compared to the same period of 2021. The increase in revenue was primarily driven by an increase in the volume of EksoNR device sales in the EMEA and APAC regions. EksoWorks revenue decreased approximately $0.2 million for the three months ended September 30, 2022, compared to the same period of 2021. The decrease in EksoWorks revenue was primarily driven by a reduction in the volume of EVO and EksoVest sales.

Gross Profit

Gross profit decreased 7% for the three months ended September 30, 2022 compared to the same period of 2021, driven by a decrease in gross profit margins in EksoHealth and EksoWorks segments. Gross margin was approximately 51% for the three months ended September 30, 2022, compared to a gross margin of 59% for the same period of 2021. The overall decrease in gross margin was primarily due to the increase in EksoHealth service costs for both labor and materials usage, and increases in inventory costs due to the continued global supply shortage. Additionally, the average selling price for the EksoNR, on an aggregate basis across all regions, for the three months ended September 30, 2022 decreased 12% compared to the same period in 2021 as a result of a relative increase of indirect device sales placed through our distributors. The decrease in gross margin was partially offset by the relative increase in EksoHealth revenue, which generally has higher gross margins, in overall revenue composition.

EksoHealth service costs increased due to increased headcount, significant increases in the cost of shipping and freight related to service activities, and the servicing of on an increased number of customer units.

Operating Expenses

Research and development expenses increased $0.3 million, or 51%, for the three months ended September 30, 2022, compared to the same period of 2021, primarily due to an increase in product development activity mostly related to sustaining engineering activity for the EksoNR and the development of next generation products.

General and administrative expenses increased $0.4 million, or 16%, for the three months ended September 30, 2022, compared to the same period of 2021, primarily due to an increase in business development activities and costs associated with our move to our new headquarters and manufacturing facility in San Rafael, California.

Total Other (Expense) Income, Net

Gain on revaluation of warrant liabilities was $0.1 million for the three months ended September 30, 2022, and was associated with the revaluation of warrants issued in 2019, 2020 and 2021. Gain on warrant liabilities was $1.1 million for the three months ended September 30, 2021, and was associated with the revaluation of warrants issued in 2019, 2020 and 2021. Gains and losses on revaluation of warrants are primarily driven by changes in our stock price and the risk-free rate.

Unrealized loss on foreign exchange for the three months ended September 30, 2022 was $0.7 million compared to an unrealized loss on foreign exchange of $0.3 million for the same period of 2021. The unrealized loss was primarily the result of foreign currency revaluations of our inter-company monetary assets and liabilities.

The following table presents our results of operations for the nine months ended September 30, 2022 and 2021 (in thousands, except percentages):

	Nine Months Ended September 30,
	2022			2021			Change		% Change
Revenue	$	9,361		$	7,170		$	2,191	31	%
Cost of revenue	4,825			2,836			1,989		70	%
Gross profit	4,536			4,334			202		5	%
Gross profit %	48		%	60		%
Operating expenses:
Sales and marketing	5,212			5,265			(53)		(1)	%
Research and development	2,855			1,930			925		48	%
General and administrative	7,589			6,415			1,174		18	%
Total operating expenses	15,656			13,610			2,046		15	%
Loss from operations	(11,120)			(9,276)			(1,844)		20	%
Other (expense) income, net:
Interest expense	(90)			(77)			(13)		17	%
Gain on revaluation of warrant liabilities	1,011			2,011			(1,000)		n/m(1)
Gain on forgiveness of note payable	—			1,099			(1,099)		n/m(1)
Unrealized loss on foreign exchange	(1,704)			(640)			(1,064)		n/m(1)
Other income (expense), net	1			(18)			19		(106)	%
Total other (expense) income, net	(782)			2,375			(3,157)		(133)	%
Net loss	$	(11,902)		$	(6,901)		$	(5,001)	72	%

(1)Not Meaningful

Revenue

Revenue increased $2.2 million, or 31%, for the nine months ended September 30, 2022, compared to the same period of 2021. Revenue for the nine months ended September 30, 2022 included approximately $8.3 million in EksoHealth revenue and approximately $1.0 million in EksoWorks revenue.

EksoHealth revenue increased approximately $2.0 million, or 32%, for the nine months ended September 30, 2022, compared to the same period of 2021. The increase in revenue was primarily driven by an increase in the volume of EksoNR device sales in the Americas, EMEA, and APAC regions. EksoWorks revenue increased approximately $0.2 million, or 19%, for the nine months ended September 30, 2022, compared to the same period of 2021. The increase in revenue was primarily related to the recognition of previously deferred prepaid royalties associated with a license and distribution agreement that expired.

Gross Profit

Gross profit increased 5% for the nine months ended September 30, 2022 compared to the same period of 2021, largely driven by the increase in EksoHealth revenue as discussed above. Gross margin was approximately 48% for the nine months ended September 30, 2022, compared to a gross margin of 60% for the same period of 2021. The overall decrease in gross margin was primarily due to an increase in EksoHealth service costs for both labor and materials usage, and increases in inventory costs due to the continued global supply shortage. The decrease in gross margin was partially offset by the recognition of previously deferred prepaid royalties associated with a license and distribution agreement that expired.

EksoHealth service costs increased due to increased headcount and the servicing of an increased number of customer units, owing to the receipt of service parts during the period, the shortage of which had previously precluded the completion of service. Additionally, we have experienced significant increases in the cost of shipping and freight related to service activities.

Operating Expenses

Research and development expenses increased $0.9 million, or 48%, for the nine months ended September 30, 2022, compared to the same period of 2021, due to an increase in product development activity mostly related to sustaining engineering activity for the EksoNR.

General and administrative expenses increased $1.2 million, or 18%, for the nine months ended September 30, 2022, compared to the same period of 2021, primarily due to noncash stock-based compensation related to the appointment of our new Chief Executive Officer, severance expense associated with the departure of our former Chief Executive Officer, an increase in business development activities, and costs associated with our move to our new headquarters and manufacturing facility in San Rafael, California.

Total Other (Expense) Income, Net

Gain on revaluation of warrant liabilities was $1.0 million for the nine months ended September 30, 2022, and was associated with the revaluation of warrants issued in 2019, 2020 and 2021. Gain on warrant liabilities was $2.0 million for the nine months ended September 30, 2021, and was associated with the revaluation of warrants issued in 2019, 2020 and 2021. Gains and losses on revaluation of warrants are primarily driven by changes in our stock price and risk free rate.

Gain on forgiveness of note payable of $1.1 million for the nine months ended September 30, 2021, related to the forgiveness of our PPP Loan. There was no comparable item in the nine months ended September 30, 2022.

Unrealized loss on foreign exchange for the nine months ended September 30, 2022 was $1.7 million compared to an unrealized loss on foreign exchange of $0.6 million for the same period of 2021. The unrealized loss was primarily due to foreign currency revaluations of our inter-company monetary assets and liabilities.

Liquidity and Capital Resources

Since our inception, we have devoted substantially all of our efforts toward the development and commercialization of exoskeletons for the medical and industrial markets. and toward raising capital. We have financed our operations primarily through the issuance and sale of equity securities for cash consideration and through bank debt.

Liquidity and Capital Resources

On September 30, 2022, we had working capital of $28.9 million, compared to working capital of $40.9 million at December 31, 2021. The decrease in working capital was primarily due to a lower cash balance from cash used in operations. Our cash as of September 30, 2022, consisted of bank deposits with third party financial institutions. As of September 30, 2022, of our $29.2 million of cash, $28.1 million was held domestically while $1.1 million was held by foreign subsidiaries.

As described in Note 8 in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q under the caption Notes Payable, net, borrowings under our new secured term loan agreement with Pacific Western Bank have a requirement of minimum cash on hand equivalent to the current outstanding principal balance. As of September 30, 2022, $2.0 million of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of September 30, 2022 is estimated to be $27.2 million. With this unrestricted cash balance, we believe that we currently have sufficient cash to fund our operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.

Cash

The following table summarizes the sources and uses of cash (in thousands).

	Nine months ended September 30,
	2022		2021
Net cash used in operating activities	$	(11,044)	$	(8,081)
Net cash used in investing activities	(141)		(60)
Net cash provided by financing activities	—		38,712
Effect of exchange rate changes on cash	(41)		6
Net (decrease) increase in cash	(11,226)		30,577
Cash at the beginning of the period	40,406		12,862
Cash at the end of the period	$	29,180	$	43,439

Net Cash Used in Operating Activities

Net cash used in operations increased $3.0 million, or 37%, for the nine months ended September 30, 2022, compared to the same period of 2021 primarily due to higher payments for business development costs incurred in late 2021, increased employee compensation, and increased inventory purchases.

Net Cash Used in Investing Activities

Net cash used in investing activities increased $0.1 million for the nine months ended September 30, 2022, compared to the same period of 2021 due to cash outflows for leasehold improvements for our new headquarters and manufacturing facility in San Rafael, California.

Net Cash Provided by Financing Activities

Net cash provided by financing activities of $38.7 million for the nine months ended September 30, 2021, was generated from the sale of common stock and warrants for net proceeds of $36.5 million in connection with the equity financing, net proceeds of $0.7 million from our “at the market offering” program, and proceeds of $1.4 million from the exercise of warrants. There was no comparable amount for the nine months ended September 30, 2022.

Material Cash Requirements

Our material cash requirements include the following items, some of which are represented in the table of Contractual Obligations and Commitments: (1) employee wages, benefits and incentives, (2) the procurement of raw materials and components to support the manufacturing and sale of our products, (3) expenditures for the ongoing improvement and development of existing and new technologies, (4) debt repayments (for additional information see Note 8 in the notes to our condensed consolidated financial statements included elsewhere in the Quarterly Report on Form 10-Q), and (5) operating lease payments (for additional information see Note 9 in the notes to our condensed consolidated financial statements included elsewhere in the Quarterly Report on Form 10-Q).

We plan on utilizing our existing unrestricted cash balance to fund our material cash requirements in the short and long term.

Contractual Obligations and Commitments

The following table summarizes our outstanding contractual obligations as of September 30, 2022, and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):

	Payments Due By Period:
	Total		Less than One Year		1-3 Years		3-5 Years
Note payable, principal and interest	$	2,124	$	2,124	$	—	$	—
Facility operating leases	1,579		314		822		443
Purchase obligations	3,203		3,203		—		—
Total	$	6,906	$	5,641	$	822	$	443

In response to, or in anticipation of, supplier disruptions and extended lead times, we may stockpile certain components or raw materials to help prevent disruption in our production of the EksoNR. Such purchasing behavior is a contributing factor to the increase in purchase obligations as compared to prior periods. These actions have, and could continue to have, a short-term adverse impact on our cash used in operating activities and increase our inventory balance. Obligations related to these activities are reflected in the line purchase obligations in the table above.

Refer to Note 13. Commitments and Contingencies in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information regarding our license agreements, purchase obligations, and lease commitments.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

There have been no material changes in our market risk during the nine months ended September 30, 2022, compared to the disclosures in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 4. Controls and Procedures

Disclosure Controls and Procedures.

Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as of the end of the period covered by this Quarterly Report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

It should be noted that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment and makes assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. Management believes that the financial statements included in this Quarterly Report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we are subject to legal proceedings and claims arising in the ordinary course of business. Based on our current knowledge, we believe that the amount or range of reasonably possible losses will not, either individually or in the aggregate, have a material adverse effect on our business, results of operations, or financial condition.

The results of any litigation cannot be predicted with certainty, and an unfavorable resolution in any legal proceedings could materially affect our future business, results of operations, or financial condition. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. For additional information, please refer to Note 13. Commitments and Contingencies in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

We have not identified any material changes to the risk factors previously disclosed in Part I - Item 1A - “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 6. Exhibits

 

Exhibit Number	Description
10.1*	Lease, dated July, 15, 2022, between Don Tornberg and Ekso Bionics, Inc.
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.
32.1+	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2+	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	The following financial statements from the Ekso Bionics Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Extensible Business Reporting Language (“XBRL”):
	•	unaudited condensed consolidated balance sheets;
	•	unaudited condensed consolidated statements of operations and comprehensive income (loss);
	•	unaudited condensed consolidated statements of stockholders’ equity;
	•	unaudited condensed consolidated statement of cash flows; and
	•	notes to unaudited condensed consolidated financial statements.

*	Filed herewith.
+	Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Ekso Bionics Holdings, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	EKSO BIONICS HOLDINGS, INC.
Date: November 3, 2022	By:	/s/ Steven Sherman
		Steven Sherman
		Chief Executive Officer and Chairman
		(Principal Executive Officer)
Date: November 3, 2022	By:	/s/ Jerome Wong
		Jerome Wong
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-10.1

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Steven Sherman, certify that:

(1)I have reviewed this Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc.;

(2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

(4)The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

(5)The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: November 3, 2022

/s/ Steven Sherman

Steven Sherman

Principal Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Jerome Wong, certify that:

(1)I have reviewed this Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc.;

(2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

(4)The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

(5)The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: November 3, 2022

/s/ Jerome Wong

Jerome Wong

Principal Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

In connection with the Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc. (the “Company”), for the quarterly period ended September 30, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Steven Sherman, Chief Executive Officer and principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: November 3, 2022

/s/ Steven Sherman

Steven Sherman

Principal Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

In connection with the Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc. (the “Company”), for the quarterly period ended September 30, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Jerome Wong, Chief Financial Officer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: November 3, 2022

/s/ Jerome Wong

Jerome Wong

Principal Financial Officer

XML

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-37854
Entity Registrant Name	Ekso Bionics Holdings, Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	99-0367049
Entity Address, Address Line One	101 Glacier Point
Entity Address, Address Line Two	Suite A
Entity Address, City or Town	San Rafael
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94901
City Area Code	510
Local Phone Number	984-1761
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	EKSO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,142,418
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001549084
Current Fiscal Year End Date	--12-31

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 29,180	$ 40,406
Accounts receivable, net of allowances of $30 and $28, respectively	3,398	4,662
Inventories	3,508	2,242
Prepaid expenses and other current assets	668	485
Total current assets	36,754	47,795
Property and equipment, net	959	991
Right-of-use assets	1,374	216
Other assets	224	164
Total assets	39,311	49,166
Current liabilities:
Accounts payable	2,387	3,107
Accrued liabilities	2,172	2,299
Deferred revenues, current	1,059	1,220
Note payable, current	1,996	0
Lease liabilities, current	244	229
Total current liabilities	7,858	6,855
Deferred revenues	1,032	1,475
Note payable, net	0	1,993
Lease liabilities	1,167	0
Warrant liabilities	539	1,550
Other non-current liabilities	101	74
Total liabilities	10,697	11,947
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 141,429 shares authorized; 13,127 and 12,693 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	13	13
Additional paid-in capital	247,884	246,090
Accumulated other comprehensive income (loss)	1,486	(17)
Accumulated deficit	(220,769)	(208,867)
Total stockholders’ equity	28,614	37,219
Total liabilities and stockholders’ equity	$ 39,311	$ 49,166

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for accounts receivable	$ 30	$ 28
Convertible Preferred stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Convertible Preferred stock, shares issued (in shares)	0	0
Convertible Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	141,429,000	141,429,000
Common stock, shares issued (in shares)	13,127,000	12,693,000
Common stock, shares outstanding (in shares)	13,127,000	12,693,000

XML

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 3,329	$ 3,049	$ 9,361	$ 7,170
Cost of revenue	1,643	1,242	4,825	2,836
Gross profit	1,686	1,807	4,536	4,334
Operating expenses:
Sales and marketing	1,742	1,685	5,212	5,265
Research and development	936	618	2,855	1,930
General and administrative	2,662	2,293	7,589	6,415
Total operating expenses	5,340	4,596	15,656	13,610
Loss from operations	(3,654)	(2,789)	(11,120)	(9,276)
Other (expense) income, net:
Interest expense	(34)	(24)	(90)	(77)
Gain on revaluation of warrant liabilities	112	1,125	1,011	2,011
Gain on forgiveness of note payable	0	0	0	1,099
Unrealized loss on foreign exchange	(732)	(268)	(1,704)	(640)
Other income (expense), net	4	(2)	1	(18)
Total other (expense) income, net	(650)	831	(782)	2,375
Net loss	(4,304)	(1,958)	(11,902)	(6,901)
Other comprehensive income	652	261	1,503	601
Comprehensive loss	$ (3,652)	$ (1,697)	$ (10,399)	$ (6,300)
Net loss per share applicable to common shareholders, basic (in dollars per share)	$ (0.33)	$ (0.15)	$ (0.92)	$ (0.57)
Net loss per share applicable to common shareholders, diluted (in dollars per share)	$ (0.33)	$ (0.17)	$ (0.92)	$ (0.62)
Weighted average number of shares outstanding, basic (in shares)	13,071	12,661	12,896	12,029
Weighted average number of shares outstanding, diluted (in shares)	13,071	12,710	12,896	12,133

XML

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Convertible Preferred Stock Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020		0	8,349
Beginning balance at Dec. 31, 2020	$ 4,434	$ 0	$ 8	$ 204,376	$ (847)	$ (199,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,670)					(3,670)
Issuance of common stock under:
Equity financing, net (in shares)			3,980
Equity financing, net	35,360		$ 4	35,356
Exercise of warrants (in shares)			300
Exercise of warrants	3,878		$ 1	3,877
Matching contribution to 401(k) plan (in shares)			26
Matching contribution to 401(k) plan	152			152
Stock-based compensation expense	356			356
Foreign currency translation adjustments	465				465
Ending balance (in shares) at Mar. 31, 2021		0	12,655
Ending balance at Mar. 31, 2021	40,975	$ 0	$ 13	244,117	(382)	(202,773)
Beginning balance (in shares) at Dec. 31, 2020		0	8,349
Beginning balance at Dec. 31, 2020	4,434	$ 0	$ 8	204,376	(847)	(199,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (6,901)
Issuance of common stock under:
Matching contribution to 401(k) plan (in shares)	26
Matching contribution to 401(k) plan	$ 152
Ending balance (in shares) at Sep. 30, 2021		0	12,664
Ending balance at Sep. 30, 2021	39,062	$ 0	$ 13	245,299	(246)	(206,004)
Beginning balance (in shares) at Mar. 31, 2021		0	12,655
Beginning balance at Mar. 31, 2021	40,975	$ 0	$ 13	244,117	(382)	(202,773)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(1,273)					(1,273)
Issuance of common stock under:
Stock-based compensation expense	519			519
Foreign currency translation adjustments	(125)				(125)
Ending balance (in shares) at Jun. 30, 2021		0	12,655
Ending balance at Jun. 30, 2021	40,096	$ 0	$ 13	244,636	(507)	(204,046)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(1,958)					(1,958)
Issuance of common stock under:
Equity incentive plan (in shares)			9
Stock-based compensation expense	663			663
Foreign currency translation adjustments	261				261
Ending balance (in shares) at Sep. 30, 2021		0	12,664
Ending balance at Sep. 30, 2021	39,062	$ 0	$ 13	245,299	(246)	(206,004)
Beginning balance (in shares) at Dec. 31, 2021		0	12,693
Beginning balance at Dec. 31, 2021	37,219	$ 0	$ 13	246,090	(17)	(208,867)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,620)					(4,620)
Issuance of common stock under:
Matching contribution to 401(k) plan (in shares)			68
Matching contribution to 401(k) plan	176			176
Equity incentive plan (in shares)			83
Stock-based compensation expense	499			499
Foreign currency translation adjustments	212				212
Ending balance (in shares) at Mar. 31, 2022		0	12,844
Ending balance at Mar. 31, 2022	33,486	$ 0	$ 13	246,765	195	(213,487)
Beginning balance (in shares) at Dec. 31, 2021		0	12,693
Beginning balance at Dec. 31, 2021	37,219	$ 0	$ 13	246,090	(17)	(208,867)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (11,902)
Issuance of common stock under:
Matching contribution to 401(k) plan (in shares)	68
Matching contribution to 401(k) plan	$ 176
Ending balance (in shares) at Sep. 30, 2022		0	13,127
Ending balance at Sep. 30, 2022	28,614	$ 0	$ 13	247,884	1,486	(220,769)
Beginning balance (in shares) at Mar. 31, 2022		0	12,844
Beginning balance at Mar. 31, 2022	33,486	$ 0	$ 13	246,765	195	(213,487)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,978)					(2,978)
Issuance of common stock under:
Equity incentive plan (in shares)			166
Stock-based compensation expense	582			582
Foreign currency translation adjustments	639				639
Ending balance (in shares) at Jun. 30, 2022		0	13,010
Ending balance at Jun. 30, 2022	31,729	$ 0	$ 13	247,347	834	(216,465)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,304)					(4,304)
Issuance of common stock under:
Equity incentive plan (in shares)			117
Stock-based compensation expense	537			537
Foreign currency translation adjustments	652				652
Ending balance (in shares) at Sep. 30, 2022		0	13,127
Ending balance at Sep. 30, 2022	$ 28,614	$ 0	$ 13	$ 247,884	$ 1,486	$ (220,769)

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (11,902)	$ (6,901)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	632	782
Changes in allowance for doubtful accounts	(11)	48
Gain on forgiveness of note payable	0	(1,099)
Gain on revaluation of warrant liabilities	(1,011)	(2,011)
Stock-based compensation expense	1,618	1,538
Common stock contribution to 401(k) plan	147	141
Unrealized loss on foreign currency transactions	1,704	640
Changes in operating assets and liabilities:
Accounts receivable	1,044	(10)
Inventories	(1,477)	(171)
Prepaid expenses and other assets, current and noncurrent	(277)	(251)
Accounts payable	(704)	(189)
Accrued, lease and other liabilities, current and noncurrent	(270)	(70)
Deferred revenues	(537)	(528)
Net cash used in operating activities	(11,044)	(8,081)
Investing activities:
Acquisition of property and equipment	(141)	(60)
Net cash used in investing activities	(141)	(60)
Financing activities:
Proceeds from issuance of common stock and warrants, net	0	37,295
Proceeds from exercise of warrants	0	1,417
Net cash provided by financing activities	0	38,712
Effect of exchange rate changes on cash	(41)	6
Net (decrease) increase in cash	(11,226)	30,577
Cash at beginning of period	40,406	12,862
Cash at end of period	29,180	43,439
Supplemental disclosure of cash flow activities
Cash paid for interest	88	69
Cash paid for income taxes	14	0
Supplemental disclosure of non-cash activities
Fair value of warrants issued upon equity financing	0	1,936
Reclassification of warrant liability to equity upon exercise of warrants	0	2,461
Transfer of inventory to property and equipment	192	387
Initial recognition of operating lease liabilities and right of use assets	1,459	0
Share issuance for common stock contribution to 401(k) plan	$ 176	$ 152

XML

Organization

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Organization

Description of Business

Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and by persons with physical disabilities. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI"), to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol “EKSO”.

Liquidity and Capital Resources

As of September 30, 2022, the Company had an accumulated deficit of $220,769.  Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the nine months ended September 30, 2022, the Company used $11,044 of cash in its operations. Cash on hand as of September 30, 2022 was $29,180.

As described in Note 8, Notes payable, net, borrowings under the Company’s secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of September 30, 2022, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of September 30, 2022 is approximately $27,180. With this unrestricted cash balance, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.

XML

Basis of Presentation and Summary of Significant Accounting Policies and Estimates

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies and Estimates

Basis of Presentation and Summary of Significant Accounting Policies and Estimates

Basis of Presentation and Consolidation

The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 24, 2022.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.

The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any future periods.

The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.

Reclassifications

During the nine months ended September 30, 2022, the Company reclassified the amortization of operating lease right-of-use assets in its condensed consolidated statements of cash flows. Amounts amortized related to operating lease right-of-use assets

have been reclassified to "Depreciation and amortization" from "Prepaid expenses and other assets, current and noncurrent" as applicable. Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects. These reclassifications did not affect changes in cash flow used in operating activities or net (decrease) in cash for the nine months ended September 30, 2021.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue, the valuation of warrants and employee equity awards, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.

Foreign Currency

The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.

Inventory

Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.

Leases

The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.

Revenue Recognition

The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.

The Company exercised judgement to determine that a product returns reserve was not required as historical returns activity have not been material.

Going Concern

The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.

Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of September 30, 2022 and December 31, 2021. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon collecting receivables denominated in a foreign currency.

At September 30, 2022, the Company had two customers (13% and 12%) with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable, as compared with zero customers at December 31, 2021.

During the three months ended September 30, 2022, the Company had two customers with sales of 10% or more of the Company’s total revenue (20% and 14%), as compared with none in the three months ended September 30, 2021.

During the nine months ended September 30, 2022, the Company had one customer with sales of 10% or more of the Company’s total revenue (14%), as compared with none in the nine months ended September 30, 2021.

Recent Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2022-02, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company beginning in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its condensed consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2024 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2020-06 to be material on its consolidated financial statements.

XML

Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss)

The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the nine months ended September 30, 2022 and 2021, is reflected in the table below net of tax:

	Nine Months Ended September 30,
	2022		2021
Balance at beginning of period	$	(17)	$	(847)
Net unrealized gain on foreign currency translation	1,503		601
Balance at end of period	$	1,486	$	(246)

XML

Fair Value Measurement

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurement

Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:

•Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.

The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:

	Total		Level 1		Level 2		Level 3
September 30, 2022
Liabilities
Warrant liabilities	$	539	$	—	$	—	$	539
December 31, 2021
Liabilities
Warrant liabilities	$	1,550	$	—	$	—	$	1,550

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2022, which were measured at fair value on a recurring basis:

	Warrant Liability
Balance at December 31, 2021	$	1,550
Gain on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings	(1,011)
Balance at September 30, 2022	$	539

Refer to Note 10. Capitalization and Equity Structure – Warrants for additional information regarding the valuation of warrants.

XML

Inventories

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventories consisted of the following:

	September 30, 2022		December 31, 2021
Raw materials	$	2,845	$	2,061
Work in progress	373		145
Finished goods	290		36
Inventories	$	3,508	$	2,242

XML

Revenue

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenue

Revenue

The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, the sale of support and maintenance contracts (Ekso Care), and the sale of accessories for the EksoNR. In 2021, the Company moved to a customer subscription sales model and away from a rental sales model. Under the rental sales model, the Company offered customers a short-term rental arrangement of its products to help bridge to a capital purchase since customers typically have challenges in obtaining approvals for capital expenditures. Subscription sales arrangements, however, bypass the customer capital purchase process, are intended to renew annually, and provide a long-term revenue stream.

Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements. The separately priced Ekso Care contracts range from 12 to 48 months. The Company receives payment at the

inception of the contract and recognizes revenue evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the initial contract term, typically over 12 to 24 months.

The Company’s industrial device segment (EksoWorks) revenue is generated through the sale of the upper body exoskeletons (EksoVest and the EVO) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility.

At the end of the second quarter of 2022, the Company ceased commercialization of the EksoZeroG support arm and related products and accessories. The Company may continue to sell parts and accessories to existing EksoZeroG customers to deplete its current stock of EksoZeroG inventories, however, the Company does not expect any future revenues derived from the sale of the EksoZeroG product line to have a material contribution to EksoWorks segment revenues. Refer to Note 13 Commitment and Contingencies for further information regarding commitments and obligations related to the EksoZeroG product line.

Deferred Revenue

For the sale of its products, the Company recognizes revenue upon the transfer of control of products to its customers, typically upon shipment from its facilities. For the subscription of its products, the Company generally recognizes revenue over the subscription term commencing upon the completion of customer training. For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.

Deferred revenue is comprised mainly of unearned revenue related to service agreement contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.

Deferred revenue consisted of the following:

	September 30, 2022		December 31, 2021
Deferred extended maintenance and support	$	2,056	$	2,349
Deferred royalties	—		280
Customer advances	35		66
Total deferred revenues	2,091		2,695
Less current portion	(1,059)		(1,220)
Deferred revenues, non-current	$	1,032	$	1,475

Deferred revenue activity consisted of the following for the nine months ended September 30, 2022:

Beginning balance	$	2,695
Deferral of revenue	1,014
Recognition of deferred revenue	(1,618)
Ending balance	$	2,091

As of September 30, 2022, the Company’s deferred revenue was $2,091. The Company expects to recognize approximately $375 of the deferred revenue during the remainder of 2022, $897 in 2023, and $819 thereafter.

In addition to deferred revenue, the Company has a non-cancellable backlog of $2,527 related to its contracts for subscription units with its customers. These subscription contracts typically have 12 to 24 month terms, and subscription income is recognized on a straight-line basis over the term of the contract.

In the nine months ended September 30, 2022, the Company recognized revenue of $280 related to a $300 upfront royalty payment associated with a license and distribution agreement that expired. The unrecognized royalty balance of $280 was included in deferred revenue as of December 31, 2021.

As of September 30, 2022 and December 31, 2021, total accounts receivable, net of allowance for doubtful accounts, were $3,536 and $4,824, respectively, and are included in accounts receivable, net and other assets on the Company’s condensed consolidated balance sheets.

The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source for the three months ended September 30, 2022:

	EksoHealth		EksoWorks		Total
Device revenue	$	2,338	$	72	$	2,410
Service and support	484		—		484
Subscriptions	237		14		251
Parts and other	165		19		184
	$	3,224	$	105	$	3,329

The following table disaggregates the Company’s revenue by major source for the nine months ended September 30, 2022:

	EksoHealth		EksoWorks		Total
Device revenue	$	5,670	$	544	$	6,214
Service and support	1,440		—		1,440
Subscriptions	678		134		812
Parts and other	438		350		788
Collaborative arrangements	107		—		107
	$	8,333	$	1,028	$	9,361

The following table disaggregates the Company’s revenue by major source for the three months ended September 30, 2021:

	EksoHealth		EksoWorks		Total
Device revenue	$	1,791	$	240	$	2,031
Service and support	477		—		477
Rentals and subscriptions	173		66		239
Parts and other	233		27		260
Collaborative arrangements	42		—		42
	$	2,716	$	333	$	3,049

The following table disaggregates the Company’s revenue by major source for the nine months ended September 30, 2021:

	EksoHealth		EksoWorks		Total
Device revenue	$	3,900	$	625	$	4,525
Service and support	1,412		—		1,412
Rentals and subscriptions	510		188		698
Parts and other	427		51		478
Collaborative arrangements	57		—		57
	$	6,306	$	864	$	7,170

XML

Accrued Liabilities

9 Months Ended

Sep. 30, 2022

Accrued Liabilities and Other Liabilities [Abstract]

Accrued Liabilities

Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2022		December 31, 2021
Salaries, benefits and related expenses	$	1,822	$	2,015
Device warranty	224		195
Other	126		89
Total	$	2,172	$	2,299

The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three and nine months ended September 30, 2022 is as follows:

	Three Months Ended		Nine Months Ended
	September 30, 2022		September 30, 2022
Balance at beginning of period	$	275	$	270
Additions for estimated future costs	124		256
Incurred costs	(74)		(201)
Balance at end of period	$	325	$	325
			Balance as of September 30, 2022
Current portion			$	224
Long-term portion			101
Total			$	325

XML

Notes Payable, net

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Notes Payable, net

Notes Payable, net

PWB Term Loan

In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its “prime rate” then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.

The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.

The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of September 30, 2022. On September 30, 2022, with cash on hand of $29,180, the Company was compliant with this liquidity covenant and all other covenants.

The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 6.45% and 5.37% for the three and nine months ended September 30, 2022, respectively. The debt issuance costs are amortized to interest expense using the effective interest method over the life of the loan.

The following table presents scheduled principal payments of the Company’s PWB term loan as of September 30, 2022:

Period	Amount
Remainder of 2022	$	—
2023	2,000
Total principal payments	2,000
Less debt discount and issuance cost	4
Note payable, net	$	1,996
Current portion	$	1,996
Long-term portion	—
Note payable, net	$	1,996

Paycheck Protection Program Loan

On April 20, 2020, the Company received an unsecured loan (the "PPP Loan") in the principal amount of $1,086 under the Paycheck Protection Program (the “PPP”) administered by the U.S. Small Business Administration (the "SBA"), pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan bore interest at 1.00% per annum, and matured two years after the date of initial disbursement. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, (the "PPP Flexibility Act"), which was enacted on June 5, 2020. The PPP Loan was used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments and interest payments on other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company could apply for and be granted forgiveness for all or a portion of the PPP Loan, with such forgiveness to be determined, subject to limitations (including whether employees of the Company have been terminated and not re-hired by a certain date), based on the use of the PPP Loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness were also subject to further requirements in regulations and guidelines adopted by the SBA.

On June 28, 2021, the Company received notification from the SBA that the Company’s forgiveness application for the PPP Loan and accrued interest, totaling $1,099, was approved in full, and the Company had no further obligations related to the PPP Loan. Accordingly, the Company recorded a gain on the forgiveness of the PPP Loan as gain on forgiveness of note payable on the condensed consolidated statement of operations during the nine months ended September 30, 2021.

XML

Lease Obligations

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Lease Obligations

Lease ObligationsThe Company maintained a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California (the "Richmond Lease") which expired at the end of May 2022. The Company continued to maintain its tenancy at this location until the end of August 2022. Pursuant to the terms of the original lease agreement, the Company incurred monthly

expenses equal to the most recent monthly lease payment under the now expired lease agreement and common area maintenance costs plus a 25% mark-up.

In July 2022, the Company entered into an operating lease agreement for its new headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") expiring in October 2026 with the option to renew for an additional three-year period at the prevailing market rate at the time of extension. At the end of August 2022, the Company relocated to its new headquarters and manufacturing facility in San Rafael.

The Company has determined that the new San Rafael Lease constitutes an operating lease under ASC 842 and estimates the lease term as July 2022 through October 2026. The option to extend for a three-year period lacks significant economic incentives and disincentives, which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for the San Rafael Lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company previously maintained a five-year operating lease agreement for its European operations office in Hamburg, Germany, which was originally set to expire in July 2022. In February 2022, the Company executed a new lease agreement with the same landlord for a replacement office in Hamburg, Germany commencing May 1, 2022 and expiring June 30, 2025 with an option to renew for one five-year period. Upon the early termination of the previous lease agreement, it was agreed between the landlord and the Company that access to the previously leased office space would be revoked and the Company would be relieved of its payment obligations for the final two months of the lease term. Consequently, the Company removed the right of use asset and lease liability, $15 and $16 respectively, recorded in its condensed consolidated financial statements related to the original Hamburg tenancy.

The Company has determined that the new Hamburg lease agreement constitutes a lease under ASC 842 and estimates the lease term as May 2022 through June 2025. The option to extend for a five-year period lacks significant economic incentives and disincentives which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company’s future lease payments as of September 30, 2022, which are presented as Lease liabilities, current and Lease liabilities on the Company’s condensed consolidated balance sheets are as follows:

Periods	Operating Leases
Remainder of 2022	$	13
2023	403
2024	415
2025	399
2026	349
Total lease payments	1,579
Less: imputed interest	(168)
Present value of lease liabilities	$	1,411
Weighted-average remaining lease term (in years)	3.95
Weighted-average discount rate	5.4		%

Lease expense under the Company’s operating leases was $189 and $130 for the three months ended September 30, 2022 and 2021, respectively, and $455 and $395 for the nine months ended September 30, 2022 and 2021, respectively.

XML

Capitalization and Equity Structure

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Capitalization and Equity Structure

Capitalization and Equity Structure

Summary

The Company’s authorized capital stock at September 30, 2022 and December 31, 2021 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. As of September 30, 2022 and December 31, 2021, there were 13,127 and 12,693, respectively, shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

Common Stock

February 2021 Offering

In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for a public price of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering"). The Company received net proceeds of $36,504 from the February 2021 Offering after deducting underwriting discounts, commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued, to certain designees of Wainwright, five-year warrants (the “2021 Warrants”) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering, or 273 shares, at an exercise price of $12.81 per share.

At the Market Offering

In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. The Company may offer and sell shares having an aggregate offering price of up to $7,500 under the registration statement and prospectus supplement filed with the SEC related to such offering. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share. The Company did not sell any shares under the ATM agreement during the three and nine months ended September 30, 2022. During the nine months ended September 30, 2021, the Company sold 78 shares of common stock at an average price of $10.72 for proceeds of $791, net of commissions and issuance costs. The Company did not sell any shares under the ATM Agreement during the three months ended September 30, 2021. As of September 30, 2022, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.

Warrants

Warrants outstanding as of September 30, 2022 and December 31, 2021 were as follows:  

Source	Exercise Price		Term (Years)	December 31, 2021	Issued	Exercised	September 30, 2022
2021 Warrants	$	12.81	5	273	—	—	273
June 2020 Investor Warrants	$	5.18	5.5	127	—	—	127
June 2020 Placement Agent Warrants	$	5.64	5	39	—	—	39
December 2019 Warrants	$	8.10	5	556	—	—	556
December 2019 Placement Agent Warrants	$	8.44	5	52	—	—	52
May 2019 Warrants	$	3.52	5	193	—	—	193
				1,240	—	—	1,240

During the nine months ended September 30, 2021, the Company received net proceeds of $1,417 from the exercise of 358 warrants and issued 300 shares of common stock, respectively, as a result of those exercises. No warrants were exercised during the nine months ended September 30, 2022.

2021 Warrants

In February 2021, the Company issued the 2021 Warrants, exercisable for up to 273 shares of the Company’s common stock at an exercise price of $12.81 per share. The 2021 Warrants were exercisable immediately, and will expire five years from the date of issuance, or on February 11, 2026.

In addition, the 2021 Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its 2021 Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the 2021 Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the 2021 Warrants. The 2021 Warrants will be automatically exercised on a cashless basis on their expiration date. The 2021 Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants.

The 2021 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the 2021 Warrants, the Company or any successor entity will, at the option of a holder of a 2021 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s 2021 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s 2021 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the 2021 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the 2021 Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the 2021 Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	12.81		$	12.81
Risk-free interest rate	4.22		%	1.13		%
Expected term (years)	3.36			4.11
Volatility of stock	97.7		%	98.3		%

June 2020 Investor Warrants

In June 2020, the Company issued warrants (the "June 2020 Investor Warrants"), exercisable for up to 874 shares of the Company’s common stock at an exercise price of $5.18 per share. The June 2020 Investor Warrants were immediately exercisable, and will expire five and one-half years from the date of issuance, or on December 10, 2025.

In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.

The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the nine months ended September 30, 2022 and 2021, no shares and 270 shares of the June 2020 Investor Warrants were exercised, respectively.

The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the June 2020 Investor Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	5.18		$	5.18
Risk-free interest rate	4.23		%	1.11		%
Expected term (years)	3.19			3.94
Volatility of stock	99.5		%	103.9		%

June 2020 Placement Agent Warrants

In June 2020, the Company issued warrants (the "June 2020 Placement Agent Warrants"), exercisable for up to 122 shares of the Company’s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $5.64, subject to adjustment in certain circumstances, and will expire on June 7, 2025. During the nine months ended September 30, 2022 and 2021, no shares and 83 shares of the June 2020 Placement Agent Warrants were exercised, respectively.

Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	5.64		$	5.64
Risk-free interest rate	4.19		%	1.03		%
Expected term (years)	2.69			3.44
Volatility of stock	101.4		%	100		%

December 2019 Warrants

In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering"), the Company issued warrants (the "December 2019 Warrants") to purchase 556 shares of common stock. The December 2019 Warrants are currently exercisable, have an exercise price of $8.10 per share, and will expire five years from the date they initially became exercisable, or on June 21, 2025.

The December 2019 Warrants also contain a cashless exercise provision and could require cash payments in the event of a failure to timely deliver securities or in the event of insufficient authorized shares. The December 2019 Warrants will be automatically exercised on a cashless basis on their expiration date. The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s December 2019 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	8.10		$	8.10
Risk-free interest rate	4.19		%	1.04		%
Expected term (years)	2.72			3.47
Volatility of stock	101.3		%	99.7		%

December 2019 Placement Agent Warrants

In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase 52 shares of the Company’s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $8.44, subject to adjustment in certain circumstances, and will expire on December 18, 2025.

The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	8.44		$	8.44
Risk-free interest rate	4.09		%	0.96		%
Expected term (years)	2.22			2.97
Volatility of stock	72.9		%	102.9		%

Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.

May 2019 Warrants

In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued the warrants (the "May 2019 Warrants") to purchase 444 shares of common stock. The May 2019 Warrants are currently exercisable, have a current exercise price of $3.52 per share, and will expire five years from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company’s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $3.52 per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $4.51 per share, (y) the lowest exercise price of the June 2020 Investor Warrants, or $5.18, and (z) the lowest one-day volume-weighted average price of the Company’s Common Stock on the Nasdaq Capital Market as measured each day during the five trading day period starting on June 8, 2020, rounded to the nearest share, or $3.52. During the nine months ended September 30, 2022 and 2021, no shares and 5 shares of the May 2019 Warrants were exercised, respectively.

In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder’s warrant, elect to exercise the warrant at such variable price.

The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder’s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. Because of the price protection feature contained in the May 2019 Warrants, the Company uses a combination of the Black-Scholes Model and the Lattice Model to estimate the fair value of the warrants at each reporting period. The following assumptions were used in the Black-Scholes Model in combination with the Lattice Model to measure the fair value of the May 2019 Warrants:

	September 30, 2022			December 31, 2021
Share price	$	1.56		$	2.65
Conversion price	$	3.52		$	3.52
Risk-free interest rate	4.16		%	0.83		%
Expected term (years)	1.6			2.4
Volatility of stock	73.7		%	109.1		%

Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.

XML

Stock-based Compensation

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation

Stock-based Compensation

Shares available to grant

On June 9, 2022, the Company held its 2022 annual meeting of stockholders and ratified an amendment to the Company's Amended and Restated 2014 Equity Incentive Plan to increase the total number of shares of common stock authorized for issuance by 550 shares. As of September 30, 2022, the total shares authorized for grant under the 2014 Plan was 2,524, of which 654 were available for future grants.

Stock Options

The following table summarizes information about the Company’s stock options outstanding as of September 30, 2022, and activity during the nine months then ended:

	Stock Awards	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Balance as of December 31, 2021	491	$	32.53
Options forfeited	(51)	12.66
Options cancelled	(169)	29.82
Balance as of September 30, 2022	271	$	37.97	5.51	$	—
Vested and expected to vest at September 30, 2022	271	$	37.97	5.51	$	—
Exercisable as of September 30, 2022	259	$	39.24	5.44	$	—

As of September 30, 2022, total unrecognized compensation cost related to unvested stock options was $79. This amount is expected to be recognized as stock-based compensation expense in the Company’s condensed consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 1.02 years.

There were no stock options awarded for the three and nine months ended September 30, 2022 or the three and nine months ended September 30, 2021.

Restricted Stock Units

The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employee members of the Board. Each RSU and PSU represents the right to receive one share of the Company’s common stock upon vesting and subsequent settlement. PSUs vest upon achievement of performance targets based on the Company's annual operating plan.

The fair values of RSUs and PSUs are determined based on the closing price of the Company’s common stock on the date of grant.

Combined RSU and PSU activity for the nine months ended September 30, 2022 is summarized below:

	Number of Shares	Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2021	655	$	5.63
Granted	896	2.05
Vested	(409)	4.65
Forfeited	(193)	5.52
Unvested at September 30, 2022	949	$	2.72

As of September 30, 2022, $2,051 of total unrecognized compensation expense related to unvested RSUs and PSUs was expected to be recognized over a weighted average period of 1.61 years.

Compensation Expense

Total stock-based compensation expense related to options, RSUs and PSUs granted to employees and non-employee members of the board of directors is included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Sales and marketing	$	61	$	119	$	202	$	310
Research and development	90		74		273		184
General and administrative	386		470		1,143		1,045
	$	537	$	663	$	1,618	$	1,539

401(k) Plan Share Match

During the nine months ended September 30, 2022 and 2021, the Company issued 68 and 26 shares of common stock with a fair value of $176 and $152, to eligible employees’ deferral accounts for the 401(k) Plan matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the fiscal years ended December 31, 2021 and 2020, respectively.

The expense related to the accrual for the 401(k) plan share matching was $147 and $141 for the nine months ended September 30, 2022 and 2021, respectively.

XML

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThere were no material changes to the unrecognized tax benefits in the nine months ended September 30, 2022, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years remain open to tax examination.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Material Contracts

The Company enters various license, research collaboration and development agreements, which provide for payments to the Company primarily for technology transfer and license fees, and royalty payments on sales.

The Company has two license agreements with the Regents of the University of California to maintain exclusive rights to certain patents. The Company is required to pay 1% of net sales of licensed medical devices sold to entities other than the U.S. government. In addition, the Company is required to pay 21% of consideration collected from any sub-licensee for the grant of the sub-license.

The Company entered into a research and development collaboration agreement in December 2021 with a party that develops technologies having utility in robotic exoskeletons from research and development activities associated with a specific set of government funded research projects. Since January 2022, the Company has assisted with research and development activities in exchange for access to a worldwide, royalty free, transferable, sublicensable, exclusive license to design and market products that use or incorporate the jointly-developed technology within Ekso’s target market segments.

Under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which granted the Company an exclusive license with respect to the technology and patent rights for certain fields of use, the Company was required to pay the developer a single-digit royalty on net receipts, subject to a $50 annual minimum royalty requirement. At the end of the second quarter of 2022, the Company ceased commercialization of the EksoZeroG support arm and is no longer required to pay the developer any further royalties.

Purchase Obligations

The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Due to a variety of factors, including the COVID-19 pandemic, various materials the Company used to manufacture its products are currently experiencing shortages and supply chain disruptions. Electronic components in general, semiconductor chips, battery cells, metals and plastics, all of which are used in the Company's products, are also in shorter supply compared to prior periods, and the Company is also experiencing longer lead times for manufacturing services such as machining and tool making and increased pricing. Numerous factors, such as the ongoing pandemic or further trade tensions between the U.S. and China, may prolong or deepen these challenges.

The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $3,203 as of September 30, 2022, which are expected to be paid within one year, and $1,446 as of December 31, 2021. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.

The Company has operating lease commitments totaling $1,579 payable over 49 months related to the San Rafael and Hamburg leases disclosed in Note 9. Lease Obligations.

Contingencies

In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s condensed consolidated financial statements.

XML

Net Loss Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(4,304)	$	(1,958)	$	(11,902)	$	(6,901)
Adjustment for gain on revaluation of warrant liabilities	—		(158)		—		(643)
Net loss applicable to common stockholders, diluted	$	(4,304)	$	(2,116)	$	(11,902)	$	(7,544)
Denominator:
Weighted-average number of shares, basic	13,071		12,661		12,896		12,029
Effect of dilutive warrants	—		49		—		104
Weighted-average number of shares, diluted	13,071		12,710		12,896		12,133
Net loss per share, basic	$	(0.33)	$	(0.15)	$	(0.92)	$	(0.57)
Net loss per share, diluted	$	(0.33)	$	(0.17)	$	(0.92)	$	(0.62)

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Options to purchase common stock	271	499	271	499
Restricted stock units	949	596	949	596
Warrants for common stock	1,240	1,047	1,240	881
Total common stock equivalents	2,460	2,142	2,460	1,976

XML

Segment Disclosures

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Segment Disclosures

Segment Disclosures

The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.

The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.

Segment reporting information is as follows:

	EksoHealth		EksoWorks		Total
Three months ended September 30, 2022
Revenue	$	3,224	$	105	$	3,329
Cost of revenue	1,524		119		1,643
Gross profit	$	1,700	$	(14)	$	1,686
Three months ended September 30, 2021
Revenue	$	2,716	$	333	$	3,049
Cost of revenue	1,044		198		1,242
Gross profit	$	1,672	$	135	$	1,807

	EksoHealth		EksoWorks		Total
Nine months ended September 30, 2022
Revenue	$	8,333	$	1,028	$	9,361
Cost of revenue	4,170		655		4,825
Gross profit	$	4,163	$	373	$	4,536
Nine months ended September 30, 2021
Revenue	$	6,306	$	864	$	7,170
Cost of revenue	2,326		510		2,836
Gross profit	$	3,980	$	354	$	4,334

The Company operates in the following regions: (1) Americas, (2) Europe, the Middle East, and Africa (EMEA), and (3) Asia Pacific (APAC). Individual countries with revenue greater than 10% of total revenue for the three and nine months ended September 30, 2022 and 2021 are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Americas
United States	$	1,475	$	1,777	$	4,889	$	3,914
Other	73		25		249		105
Americas	1,548		1,802		5,138		4,019
EMEA
Germany	237		313		487		845
Romania	449		121		449		121
Other	372		394		1,472		1,356
EMEA	1,058		828		2,408		2,322
APAC
Indonesia	668		—		668		—
Other	55		419		1,147		829
APAC	723		419		1,815		829
Total Revenue	$	3,329	$	3,049	$	9,361	$	7,170

XML

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 24, 2022.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.

The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any future periods.

Consolidation

The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.

Reclassifications

Reclassifications

During the nine months ended September 30, 2022, the Company reclassified the amortization of operating lease right-of-use assets in its condensed consolidated statements of cash flows. Amounts amortized related to operating lease right-of-use assets

have been reclassified to "Depreciation and amortization" from "Prepaid expenses and other assets, current and noncurrent" as applicable. Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects. These reclassifications did not affect changes in cash flow used in operating activities or net (decrease) in cash for the nine months ended September 30, 2021

Use of Estimates

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue, the valuation of warrants and employee equity awards, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.

Foreign Currency

Foreign Currency

The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.

Inventory

Inventory

Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.

Leases

Leases

The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.

Revenue Recognition

Revenue Recognition

The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.

The Company exercised judgement to determine that a product returns reserve was not required as historical returns activity have not been material.

Going Concern

Going Concern

The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.

Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of September 30, 2022 and December 31, 2021. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon collecting receivables denominated in a foreign currency.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2022-02, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company beginning in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its condensed consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2024 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2020-06 to be material on its consolidated financial statements.

Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:

•Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.

XML

Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the nine months ended September 30, 2022 and 2021, is reflected in the table below net of tax:

	Nine Months Ended September 30,
	2022		2021
Balance at beginning of period	$	(17)	$	(847)
Net unrealized gain on foreign currency translation	1,503		601
Balance at end of period	$	1,486	$	(246)

XML

Fair Value Measurement (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:

	Total		Level 1		Level 2		Level 3
September 30, 2022
Liabilities
Warrant liabilities	$	539	$	—	$	—	$	539
December 31, 2021
Liabilities
Warrant liabilities	$	1,550	$	—	$	—	$	1,550

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2022, which were measured at fair value on a recurring basis:

	Warrant Liability
Balance at December 31, 2021	$	1,550
Gain on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings	(1,011)
Balance at September 30, 2022	$	539

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories consisted of the following:

	September 30, 2022		December 31, 2021
Raw materials	$	2,845	$	2,061
Work in progress	373		145
Finished goods	290		36
Inventories	$	3,508	$	2,242

XML

Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Contracts with Customer, Assets and Liabilities

Deferred revenue consisted of the following:

	September 30, 2022		December 31, 2021
Deferred extended maintenance and support	$	2,056	$	2,349
Deferred royalties	—		280
Customer advances	35		66
Total deferred revenues	2,091		2,695
Less current portion	(1,059)		(1,220)
Deferred revenues, non-current	$	1,032	$	1,475

Deferred revenue activity consisted of the following for the nine months ended September 30, 2022:

Beginning balance	$	2,695
Deferral of revenue	1,014
Recognition of deferred revenue	(1,618)
Ending balance	$	2,091

Disaggregation of Revenue

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source for the three months ended September 30, 2022:

	EksoHealth		EksoWorks		Total
Device revenue	$	2,338	$	72	$	2,410
Service and support	484		—		484
Subscriptions	237		14		251
Parts and other	165		19		184
	$	3,224	$	105	$	3,329

The following table disaggregates the Company’s revenue by major source for the nine months ended September 30, 2022:

	EksoHealth		EksoWorks		Total
Device revenue	$	5,670	$	544	$	6,214
Service and support	1,440		—		1,440
Subscriptions	678		134		812
Parts and other	438		350		788
Collaborative arrangements	107		—		107
	$	8,333	$	1,028	$	9,361

The following table disaggregates the Company’s revenue by major source for the three months ended September 30, 2021:

	EksoHealth		EksoWorks		Total
Device revenue	$	1,791	$	240	$	2,031
Service and support	477		—		477
Rentals and subscriptions	173		66		239
Parts and other	233		27		260
Collaborative arrangements	42		—		42
	$	2,716	$	333	$	3,049

The following table disaggregates the Company’s revenue by major source for the nine months ended September 30, 2021:

	EksoHealth		EksoWorks		Total
Device revenue	$	3,900	$	625	$	4,525
Service and support	1,412		—		1,412
Rentals and subscriptions	510		188		698
Parts and other	427		51		478
Collaborative arrangements	57		—		57
	$	6,306	$	864	$	7,170

XML

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2022

Accrued Liabilities and Other Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2022		December 31, 2021
Salaries, benefits and related expenses	$	1,822	$	2,015
Device warranty	224		195
Other	126		89
Total	$	2,172	$	2,299

Product Maintenance And Warranty

A reconciliation of the changes in the device warranty liability for the three and nine months ended September 30, 2022 is as follows:

	Three Months Ended		Nine Months Ended
	September 30, 2022		September 30, 2022
Balance at beginning of period	$	275	$	270
Additions for estimated future costs	124		256
Incurred costs	(74)		(201)
Balance at end of period	$	325	$	325
			Balance as of September 30, 2022
Current portion			$	224
Long-term portion			101
Total			$	325

XML

Notes Payable, net (Tables)

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt

The following table presents scheduled principal payments of the Company’s PWB term loan as of September 30, 2022:

Period	Amount
Remainder of 2022	$	—
2023	2,000
Total principal payments	2,000
Less debt discount and issuance cost	4
Note payable, net	$	1,996
Current portion	$	1,996
Long-term portion	—
Note payable, net	$	1,996

XML

Lease Obligations (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of Maturities of Future Obligations

The Company’s future lease payments as of September 30, 2022, which are presented as Lease liabilities, current and Lease liabilities on the Company’s condensed consolidated balance sheets are as follows:

Periods	Operating Leases
Remainder of 2022	$	13
2023	403
2024	415
2025	399
2026	349
Total lease payments	1,579
Less: imputed interest	(168)
Present value of lease liabilities	$	1,411
Weighted-average remaining lease term (in years)	3.95
Weighted-average discount rate	5.4		%

XML

Capitalization and Equity Structure (Tables)

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Schedule of Warrant share activity

Warrants outstanding as of September 30, 2022 and December 31, 2021 were as follows:  

Source	Exercise Price		Term (Years)	December 31, 2021	Issued	Exercised	September 30, 2022
2021 Warrants	$	12.81	5	273	—	—	273
June 2020 Investor Warrants	$	5.18	5.5	127	—	—	127
June 2020 Placement Agent Warrants	$	5.64	5	39	—	—	39
December 2019 Warrants	$	8.10	5	556	—	—	556
December 2019 Placement Agent Warrants	$	8.44	5	52	—	—	52
May 2019 Warrants	$	3.52	5	193	—	—	193
				1,240	—	—	1,240

Schedule of assumption used in valuation

The following assumptions were used in the Black-Scholes Model to measure the fair value of the 2021 Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	12.81		$	12.81
Risk-free interest rate	4.22		%	1.13		%
Expected term (years)	3.36			4.11
Volatility of stock	97.7		%	98.3		%

The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	5.18		$	5.18
Risk-free interest rate	4.23		%	1.11		%
Expected term (years)	3.19			3.94
Volatility of stock	99.5		%	103.9		%

The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	5.64		$	5.64
Risk-free interest rate	4.19		%	1.03		%
Expected term (years)	2.69			3.44
Volatility of stock	101.4		%	100		%

The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	8.10		$	8.10
Risk-free interest rate	4.19		%	1.04		%
Expected term (years)	2.72			3.47
Volatility of stock	101.3		%	99.7		%

The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:

	September 30, 2022			December 31, 2021
Current share price	$	1.56		$	2.65
Conversion price	$	8.44		$	8.44
Risk-free interest rate	4.09		%	0.96		%
Expected term (years)	2.22			2.97
Volatility of stock	72.9		%	102.9		%

The following assumptions were used in the Black-Scholes Model in combination with the Lattice Model to measure the fair value of the May 2019 Warrants:

	September 30, 2022			December 31, 2021
Share price	$	1.56		$	2.65
Conversion price	$	3.52		$	3.52
Risk-free interest rate	4.16		%	0.83		%
Expected term (years)	1.6			2.4
Volatility of stock	73.7		%	109.1		%

XML

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes information about the Company’s stock options outstanding as of September 30, 2022, and activity during the nine months then ended:

	Stock Awards	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Balance as of December 31, 2021	491	$	32.53
Options forfeited	(51)	12.66
Options cancelled	(169)	29.82
Balance as of September 30, 2022	271	$	37.97	5.51	$	—
Vested and expected to vest at September 30, 2022	271	$	37.97	5.51	$	—
Exercisable as of September 30, 2022	259	$	39.24	5.44	$	—

Schedule of Unvested Restricted Stock Units Roll Forward

Combined RSU and PSU activity for the nine months ended September 30, 2022 is summarized below:

	Number of Shares	Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2021	655	$	5.63
Granted	896	2.05
Vested	(409)	4.65
Forfeited	(193)	5.52
Unvested at September 30, 2022	949	$	2.72

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Total stock-based compensation expense related to options, RSUs and PSUs granted to employees and non-employee members of the board of directors is included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Sales and marketing	$	61	$	119	$	202	$	310
Research and development	90		74		273		184
General and administrative	386		470		1,143		1,045
	$	537	$	663	$	1,618	$	1,539

XML

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(4,304)	$	(1,958)	$	(11,902)	$	(6,901)
Adjustment for gain on revaluation of warrant liabilities	—		(158)		—		(643)
Net loss applicable to common stockholders, diluted	$	(4,304)	$	(2,116)	$	(11,902)	$	(7,544)
Denominator:
Weighted-average number of shares, basic	13,071		12,661		12,896		12,029
Effect of dilutive warrants	—		49		—		104
Weighted-average number of shares, diluted	13,071		12,710		12,896		12,133
Net loss per share, basic	$	(0.33)	$	(0.15)	$	(0.92)	$	(0.57)
Net loss per share, diluted	$	(0.33)	$	(0.17)	$	(0.92)	$	(0.62)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Options to purchase common stock	271	499	271	499
Restricted stock units	949	596	949	596
Warrants for common stock	1,240	1,047	1,240	881
Total common stock equivalents	2,460	2,142	2,460	1,976

XML

Segment Disclosures (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment reporting information is as follows:

	EksoHealth		EksoWorks		Total
Three months ended September 30, 2022
Revenue	$	3,224	$	105	$	3,329
Cost of revenue	1,524		119		1,643
Gross profit	$	1,700	$	(14)	$	1,686
Three months ended September 30, 2021
Revenue	$	2,716	$	333	$	3,049
Cost of revenue	1,044		198		1,242
Gross profit	$	1,672	$	135	$	1,807

	EksoHealth		EksoWorks		Total
Nine months ended September 30, 2022
Revenue	$	8,333	$	1,028	$	9,361
Cost of revenue	4,170		655		4,825
Gross profit	$	4,163	$	373	$	4,536
Nine months ended September 30, 2021
Revenue	$	6,306	$	864	$	7,170
Cost of revenue	2,326		510		2,836
Gross profit	$	3,980	$	354	$	4,334

Schedule of Geographic Information

Geographic information for revenue based on location of customers is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Americas
United States	$	1,475	$	1,777	$	4,889	$	3,914
Other	73		25		249		105
Americas	1,548		1,802		5,138		4,019
EMEA
Germany	237		313		487		845
Romania	449		121		449		121
Other	372		394		1,472		1,356
EMEA	1,058		828		2,408		2,322
APAC
Indonesia	668		—		668		—
Other	55		419		1,147		829
APAC	723		419		1,815		829
Total Revenue	$	3,329	$	3,049	$	9,361	$	7,170

XML

Organization (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 220,769		$ 208,867
Cash used in operations	11,044	$ 8,081
Cash	29,180		$ 40,406
Debt covenant, unrestricted cash	2,000
Unrestricted cash	$ 27,180

XML

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details) - Customer Concentration Risk - customer	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounts Receivable
Concentration Risk [Line Items]
Number of customers		0	2		0
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk percentage			13.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk percentage			12.00%
Revenue
Concentration Risk [Line Items]
Number of customers	2		1	0
Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk percentage	20.00%		14.00%
Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk percentage	14.00%

XML

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 37,219	$ 4,434
Net unrealized gain on foreign currency translation	1,503	601
Ending balance	28,614	39,062
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(17)	(847)
Ending balance	$ 1,486	$ (246)

XML

Fair Value Measurement - Fair Value Hierarchies (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Liabilities
Warrant liabilities	$ 539	$ 1,550
Recurring
Liabilities
Warrant liabilities	539	1,550
Level 1 | Recurring
Liabilities
Warrant liabilities	0	0
Level 2 | Recurring
Liabilities
Warrant liabilities	0	0
Level 3 | Recurring
Liabilities
Warrant liabilities	$ 539	$ 1,550

XML

Fair Value Measurement - Change in Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Gain on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings	$ (112)	$ (1,125)	$ (1,011)	$ (2,011)
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance			1,550
Ending balance	$ 539		$ 539

XML

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 2,845	$ 2,061
Work in progress	373	145
Finished goods	290	36
Inventories	$ 3,508	$ 2,242

XML

Revenue - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 2,091	$ 2,695
Contract with customer, liability, non-cancellable backlog	2,527
Revenue recognized	1,618
Deferred royalties	0	280
Accounts receivable, net of allowances	3,398	4,662
Accounts Receivable, Net And Other Assets
Disaggregation of Revenue [Line Items]
Accounts receivable, net of allowances	3,536	$ 4,824
Royalty
Disaggregation of Revenue [Line Items]
Revenue recognized	280
Proceeds from upfront payment	300
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Disaggregation of Revenue [Line Items]
Remaining performance obligation, amount	$ 375
Remaining performance obligation, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Disaggregation of Revenue [Line Items]
Remaining performance obligation, amount	$ 897
Remaining performance obligation, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Disaggregation of Revenue [Line Items]
Remaining performance obligation, amount	$ 819
Remaining performance obligation, period
Minimum
Disaggregation of Revenue [Line Items]
Accounts receivable payment terms	30 days
Minimum | EksoHealth
Disaggregation of Revenue [Line Items]
Accounts receivable payment terms	12 months
Maximum
Disaggregation of Revenue [Line Items]
Accounts receivable payment terms	90 days
Maximum | EksoHealth
Disaggregation of Revenue [Line Items]
Accounts receivable payment terms	48 months

XML

Revenue - Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Deferred extended maintenance and support	$ 2,056	$ 2,349
Deferred royalties	0	280
Customer advances	35	66
Total deferred revenues	2,091	2,695
Less current portion	(1,059)	(1,220)
Deferred revenues, non-current	$ 1,032	$ 1,475

XML

Revenue - Deferred Revenue Activity (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Change In Contract With Customer, Liability Rollforward [Roll Forward]
Beginning balance	$ 2,695
Deferral of revenue	1,014
Recognition of deferred revenue	(1,618)
Ending balance	$ 2,091

XML

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 3,329	$ 3,049	$ 9,361	$ 7,170
Device revenue
Disaggregation of Revenue [Line Items]
Revenue	2,410	2,031	6,214	4,525
Service and support
Disaggregation of Revenue [Line Items]
Revenue	484	477	1,440	1,412
Subscriptions
Disaggregation of Revenue [Line Items]
Revenue	251		812
Rentals and subscriptions
Disaggregation of Revenue [Line Items]
Revenue		239		698
Parts and other
Disaggregation of Revenue [Line Items]
Revenue	184	260	788	478
Collaborative arrangements
Disaggregation of Revenue [Line Items]
Revenue		42	107	57
EksoHealth
Disaggregation of Revenue [Line Items]
Revenue	3,224	2,716	8,333	6,306
EksoHealth | Device revenue
Disaggregation of Revenue [Line Items]
Revenue	2,338	1,791	5,670	3,900
EksoHealth | Service and support
Disaggregation of Revenue [Line Items]
Revenue	484	477	1,440	1,412
EksoHealth | Subscriptions
Disaggregation of Revenue [Line Items]
Revenue	237		678
EksoHealth | Rentals and subscriptions
Disaggregation of Revenue [Line Items]
Revenue		173		510
EksoHealth | Parts and other
Disaggregation of Revenue [Line Items]
Revenue	165	233	438	427
EksoHealth | Collaborative arrangements
Disaggregation of Revenue [Line Items]
Revenue		42	107	57
EksoWorks
Disaggregation of Revenue [Line Items]
Revenue	105	333	1,028	864
EksoWorks | Device revenue
Disaggregation of Revenue [Line Items]
Revenue	72	240	544	625
EksoWorks | Service and support
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
EksoWorks | Subscriptions
Disaggregation of Revenue [Line Items]
Revenue	14		134
EksoWorks | Rentals and subscriptions
Disaggregation of Revenue [Line Items]
Revenue		66		188
EksoWorks | Parts and other
Disaggregation of Revenue [Line Items]
Revenue	$ 19	27	350	51
EksoWorks | Collaborative arrangements
Disaggregation of Revenue [Line Items]
Revenue		$ 0	$ 0	$ 0

XML

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]
Salaries, benefits and related expenses	$ 1,822	$ 2,015
Device warranty	224	195
Other	126	89
Total	$ 2,172	$ 2,299

XML

Accrued Liabilities - Product Maintenance and Warranty (Details) - Warranty $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Accrued Liabilities, Rollforward [Roll Forward]
Beginning Balance	$ 275	$ 270
Additions for estimated future costs	124	256
Incurred costs	(74)	(201)
Balance at the end	325	325
Current portion	224	224
Long-term portion	101	101
Total	$ 325	$ 325

XML

Notes Payable, net - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 28, 2021	Apr. 20, 2020	Aug. 30, 2020	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Aug. 31, 2020
Debt Instrument [Line Items]
Total principal payments				$ 2,000,000	$ 2,000,000
Cash and Cash Equivalents, at Carrying Value				29,180,000	29,180,000	$ 40,406,000
Unsecured debt
Debt Instrument [Line Items]
Interest rate		1.00%
Received net proceeds		$ 1,086,000
Debt term		2 years
Extinguishment of debt	$ 1,099,000
PWB Loan Agreement | Term Loan
Debt Instrument [Line Items]
Received loan							$ 2,000
Interest rate							4.50%
Total principal payments				$ 2,000,000	$ 2,000,000
Effective rate				6.45%	5.37%
PWB Loan Agreement | Term Loan | Prime Rate
Debt Instrument [Line Items]
Variable rate percentage			0.50%

XML

Notes Payable, net - Debt Repayment (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Remainder of 2022	$ 0
2023	2,000
Total principal payments	2,000
Less debt discount and issuance cost	4
Note payable, net	1,996
Current portion	1,996
Long-term portion	$ 0

XML

Lease Obligations - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jul. 31, 2022	Feb. 28, 2022 extension	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Right-of-use assets	$ 1,374		$ 1,374				$ 216
Lease liability	1,411		1,411
Lease expense	$ 189	$ 130	$ 455	$ 395
Richmond, California
Lessee, Lease, Description [Line Items]
Term of lease	5 years		5 years
Mark-up percentage to common area maintenance	25.00%		25.00%
San Rafael, California
Lessee, Lease, Description [Line Items]
Renewal term	3 years		3 years		3 years
Hamburg,Germany
Lessee, Lease, Description [Line Items]
Term of lease	5 years		5 years
Number of extension | extension						1
Renewal term	5 years		5 years			5 years
Lease term						2 months
Right-of-use assets	$ 15		$ 15
Lease liability	$ 16		$ 16

XML

Lease Obligations - Schedule of Lease Maturity (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
Remainder of 2022	$ 13
2023	403
2024	415
2025	399
2026	349
Total lease payments	1,579
Less: imputed interest	(168)
Present value of lease liabilities	$ 1,411
Weighted-average remaining lease term (in years)	3 years 11 months 12 days
Weighted-average discount rate	5.40%

XML

Capitalization and Equity Structure - Additional Information (Details) $ / shares in Units, $ in Thousands		1 Months Ended				2 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended
	Jun. 08, 2020	Oct. 29, 2020 USD ($) $ / shares	Jun. 30, 2020 shares	Dec. 31, 2019 $ / shares shares	May 30, 2019	Feb. 28, 2021 USD ($) $ / shares shares	Sep. 30, 2022 $ / shares shares	Sep. 30, 2021 shares	Mar. 31, 2021 shares	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Dec. 31, 2021 shares	Dec. 31, 2020 $ / shares	May 31, 2019 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)							141,429,000				141,429,000		141,429,000
Preferred Stock, shares authorized (in shares)							10,000,000				10,000,000		10,000,000
Common stock, shares outstanding (in shares)							13,127,000				13,127,000		12,693,000
Common stock, shares issued (in shares)							13,127,000				13,127,000		12,693,000
Preferred stock, shares issued (in shares)							0				0		0
Preferred stock, shares outstanding (in shares)							0				0		0
Proceeds from direct offering | $											$ 0	$ 37,295
Number warrants called (in shares)							1,240,000				1,240,000		1,240,000
Value of shares sold | $											$ 0	$ 1,417
Warrants issued (in shares)											0
Exercised (in shares)											0
Common stock
Class of Stock [Line Items]
Warrants exercised (in shares)											0	358,000
Exercise of warrants (in shares)									300,000
At-the-market offering
Class of Stock [Line Items]
Number warrants called (in shares)							0	0		78,000	0
Sale of shares (in dollars per share) | $ / shares		$ 6.75								$ 10.72
Value of shares sold | $		$ 7,500								$ 791
At-the-market offering | Common stock
Class of Stock [Line Items]
Available for future offerings | $											$ 6,668
February 2021 Offering
Class of Stock [Line Items]
Percentage of warrants issued to purchase shares of common stock						7.00%
Exercise price (in dollars per share) | $ / shares						$ 12.81
February 2021 Offering | Underwriting agreement
Class of Stock [Line Items]
Number warrants called (in shares)						3,902,000
Sale of shares (in dollars per share) | $ / shares						$ 10.25
Value of shares sold | $						$ 40,000
Proceeds from direct offering | $						$ 36,504
Expected term						5 years
2021 Warrants
Class of Stock [Line Items]
Number warrants called (in shares)						273,000	273,000				273,000
Exercise price (in dollars per share) | $ / shares						$ 12.81	$ 12.81				$ 12.81
Warrants issued (in shares)						273,000					0
Class of warrant or right expiration period						5 years					5 years
Exercised (in shares)											0
Duration of put option						30 days
Put option pay period						5 days
June 2020 Investor Warrants
Class of Stock [Line Items]
Number warrants called (in shares)			874,000				127,000				127,000		127,000
Exercise price (in dollars per share) | $ / shares							$ 5.18				$ 5.18			$ 5.18
Warrants issued (in shares)											0
Reverse stock split											0.067
Class of warrant or right expiration period											5 years 6 months
Exercised (in shares)											0	270,000
Duration of put option			30 days
June 2020 Placement Agent Warrants
Class of Stock [Line Items]
Number warrants called (in shares)							39,000				39,000		39,000
Exercise price (in dollars per share) | $ / shares														5.64
Warrants issued (in shares)			122,000								0
Class of warrant or right expiration period											5 years
Exercised (in shares)											0	83,000
December 2019 Warrants
Class of Stock [Line Items]
Number warrants called (in shares)				556,000			556,000				556,000		556,000
Exercise price (in dollars per share) | $ / shares				$ 8.10			$ 8.10				$ 8.10
Warrants issued (in shares)											0
Class of warrant or right expiration period				5 years							5 years
Exercised (in shares)											0
Duration of put option				30 days
Put option pay period				5 days
December 2019 Placement Agent Warrants
Class of Stock [Line Items]
Number warrants called (in shares)				52,000			52,000				52,000		52,000
Exercise price (in dollars per share) | $ / shares				$ 8.44			$ 8.44				$ 8.44
Warrants issued (in shares)											0
Class of warrant or right expiration period											5 years
Exercised (in shares)											0
May 2019 Warrants
Class of Stock [Line Items]
Number warrants called (in shares)							193,000				193,000		193,000		444,000
Exercise price (in dollars per share) | $ / shares							$ 3.52				$ 3.52			3.52	$ 3.52
Warrants issued (in shares)											0
Class of warrant or right expiration period											5 years
Exercised (in shares)											0	5,000
Duration of put option					90 days
Put option pay period	5 days
May 2019 Warrants | Direct offering | Common stock
Class of Stock [Line Items]
Sale of shares (in dollars per share) | $ / shares														4.51
June 2020 Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share) | $ / shares														$ 5.18
Class of warrant or right expiration period											5 years 6 months

XML

Capitalization and Equity Structure - Warrants (Details) - $ / shares	1 Months Ended		2 Months Ended	9 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Feb. 28, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2020	May 31, 2019
Class Of Warrant Or Right, Outstanding [Roll Forward]
Beginning balance (in shares)				1,240,000
Warrants issued (in shares)				0
Exercised (in shares)				0
Ending balance (in shares)				1,240,000
2021 Warrants
Schedule of Capitalization, Equity [Line Items]
Exercise price (in dollars per share)			$ 12.81	$ 12.81
Term (Years)			5 years	5 years
Class Of Warrant Or Right, Outstanding [Roll Forward]
Warrants issued (in shares)			273,000	0
Exercised (in shares)				0
Ending balance (in shares)			273,000	273,000
June 2020 Investor Warrants
Schedule of Capitalization, Equity [Line Items]
Exercise price (in dollars per share)				$ 5.18		$ 5.18
Term (Years)				5 years 6 months
Class Of Warrant Or Right, Outstanding [Roll Forward]
Beginning balance (in shares)				127,000
Warrants issued (in shares)				0
Exercised (in shares)				0	270,000
Ending balance (in shares)	874,000			127,000
June 2020 Placement Agent Warrants
Schedule of Capitalization, Equity [Line Items]
Exercise price (in dollars per share)						5.64
Term (Years)				5 years
Class Of Warrant Or Right, Outstanding [Roll Forward]
Beginning balance (in shares)				39,000
Warrants issued (in shares)	122,000			0
Exercised (in shares)				0	83,000
Ending balance (in shares)				39,000
December 2019 Warrants
Schedule of Capitalization, Equity [Line Items]
Exercise price (in dollars per share)		$ 8.10		$ 8.10
Term (Years)		5 years		5 years
Class Of Warrant Or Right, Outstanding [Roll Forward]
Beginning balance (in shares)				556,000
Warrants issued (in shares)				0
Exercised (in shares)				0
Ending balance (in shares)		556,000		556,000
December 2019 Placement Agent Warrants
Schedule of Capitalization, Equity [Line Items]
Exercise price (in dollars per share)		$ 8.44		$ 8.44
Term (Years)				5 years
Class Of Warrant Or Right, Outstanding [Roll Forward]
Beginning balance (in shares)				52,000
Warrants issued (in shares)				0
Exercised (in shares)				0
Ending balance (in shares)		52,000		52,000
May 2019 Warrants
Schedule of Capitalization, Equity [Line Items]
Exercise price (in dollars per share)				$ 3.52		$ 3.52	$ 3.52
Term (Years)				5 years
Class Of Warrant Or Right, Outstanding [Roll Forward]
Beginning balance (in shares)				193,000
Warrants issued (in shares)				0
Exercised (in shares)				0	5,000
Ending balance (in shares)				193,000

XML

Capitalization and Equity Structure - Valuation Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares
2021 Warrants | Current share price
Schedule of Capitalization, Equity [Line Items]
Current share price (in dollars per share)	$ 1.56	$ 2.65
2021 Warrants | Conversion price
Schedule of Capitalization, Equity [Line Items]
Conversion price (in dollars per share)	$ 12.81	$ 12.81
2021 Warrants | Risk-free interest rate
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.0422	0.0113
2021 Warrants | Expected term (years)
Schedule of Capitalization, Equity [Line Items]
Term (years)	3 years 4 months 9 days	4 years 1 month 9 days
2021 Warrants | Volatility of stock
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.977	0.983
June 2020 Investor Warrants | Current share price
Schedule of Capitalization, Equity [Line Items]
Current share price (in dollars per share)	$ 1.56	$ 2.65
June 2020 Investor Warrants | Conversion price
Schedule of Capitalization, Equity [Line Items]
Conversion price (in dollars per share)	$ 5.18	$ 5.18
June 2020 Investor Warrants | Risk-free interest rate
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.0423	0.0111
June 2020 Investor Warrants | Expected term (years)
Schedule of Capitalization, Equity [Line Items]
Term (years)	3 years 2 months 8 days	3 years 11 months 8 days
June 2020 Investor Warrants | Volatility of stock
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.995	1.039
June 2020 Placement Agent Warrants | Current share price
Schedule of Capitalization, Equity [Line Items]
Current share price (in dollars per share)	$ 1.56	$ 2.65
June 2020 Placement Agent Warrants | Conversion price
Schedule of Capitalization, Equity [Line Items]
Conversion price (in dollars per share)	$ 5.64	$ 5.64
June 2020 Placement Agent Warrants | Risk-free interest rate
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.0419	0.0103
June 2020 Placement Agent Warrants | Expected term (years)
Schedule of Capitalization, Equity [Line Items]
Term (years)	2 years 8 months 8 days	3 years 5 months 8 days
June 2020 Placement Agent Warrants | Volatility of stock
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	1.014	1
December 2019 Warrants | Current share price
Schedule of Capitalization, Equity [Line Items]
Current share price (in dollars per share)	$ 1.56	$ 2.65
December 2019 Warrants | Conversion price
Schedule of Capitalization, Equity [Line Items]
Conversion price (in dollars per share)	$ 8.10	$ 8.10
December 2019 Warrants | Risk-free interest rate
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.0419	0.0104
December 2019 Warrants | Expected term (years)
Schedule of Capitalization, Equity [Line Items]
Term (years)	2 years 8 months 19 days	3 years 5 months 19 days
December 2019 Warrants | Volatility of stock
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	1.013	0.997
December 2019 Placement Agent Warrants | Current share price
Schedule of Capitalization, Equity [Line Items]
Current share price (in dollars per share)	$ 1.56	$ 2.65
December 2019 Placement Agent Warrants | Conversion price
Schedule of Capitalization, Equity [Line Items]
Conversion price (in dollars per share)	$ 8.44	$ 8.44
December 2019 Placement Agent Warrants | Risk-free interest rate
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.0409	0.0096
December 2019 Placement Agent Warrants | Expected term (years)
Schedule of Capitalization, Equity [Line Items]
Term (years)	2 years 2 months 19 days	2 years 11 months 19 days
December 2019 Placement Agent Warrants | Volatility of stock
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.729	1.029
May 2019 Warrants | Current share price
Schedule of Capitalization, Equity [Line Items]
Current share price (in dollars per share)	$ 1.56	$ 2.65
May 2019 Warrants | Conversion price
Schedule of Capitalization, Equity [Line Items]
Conversion price (in dollars per share)	$ 3.52	$ 3.52
May 2019 Warrants | Risk-free interest rate
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.0416	0.0083
May 2019 Warrants | Expected term (years)
Schedule of Capitalization, Equity [Line Items]
Term (years)	1 year 7 months 6 days	2 years 4 months 24 days
May 2019 Warrants | Volatility of stock
Schedule of Capitalization, Equity [Line Items]
Measurement input percentage	0.737	1.091

XML

Stock-based Compensation - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jun. 09, 2022	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued in employee benefit plan (in shares)				68,000	26,000
Matching contribution to 401(k) plan		$ 176	$ 152	$ 176	$ 152
Percent of employee match				50.00%	50.00%
Common stock contribution				$ 147	$ 141
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued in employee benefit plan (in shares)		68,000	26,000
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense				$ 79
Unrecognized compensation expense, period of recognition				1 year 7 days
RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense				$ 2,051
Unrecognized compensation expense, period of recognition				1 year 7 months 9 days
Right to receive stock (in shares)				1
Equity Incentive Plan 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized for issuance (in shares)	550,000
Shares authorized for grant (in shares)				2,524,000
Shares available for grant (in shares)				654,000

XML

Stock-based Compensation - Stock Option Activity (Details) - 2014 Plan $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Stock Awards
Beginning balance (in shares) | shares	491
Options forfeited (in shares) | shares	(51)
Options cancelled (in shares) | shares	(169)
Ending balance (in shares) | shares	271
Options outstanding, vested and expected to vest (in shares) | shares	271
Options outstanding, exercisable (in shares) | shares	259
Weighted- Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 32.53
Options forfeited (in dollars per share) | $ / shares	12.66
Options cancelled (in dollars per share) | $ / shares	29.82
Ending balance (in dollars per share) | $ / shares	37.97
Weighted-average exercise price, vested and expected to vest (in dollars per share) | $ / shares	37.97
Weighted-average exercise price, exercisable (in dollars per share) | $ / shares	$ 39.24
Weighted-average remaining contractual life (Years), ending balance	5 years 6 months 3 days
Weighted-average remaining contractual life (Years), vested and expected to vest	5 years 6 months 3 days
Weighted-average remaining contractual life (Years), exercisable	5 years 5 months 8 days
Aggregate intrinsic value, ending balance | $	$ 0
Aggregate intrinsic value, vested and expected to vest | $	0
Aggregate intrinsic value, exercisable | $	$ 0

XML

Stock-based Compensation - RSU Activity (Details) - RSU shares in Thousands	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Shares
Beginning Balance (in shares) | shares	655
Granted (in shares) | shares	896
Vested (in shares) | shares	(409)
Forfeited (in shares) | shares	(193)
Ending Balance (in shares) | shares	949
Weighted- Average Grant Date Fair Value
Beginning Balance (in dollars per share) | $ / shares	$ 5.63
Granted (in dollars per share) | $ / shares	2.05
Vested (in dollars per share) | $ / shares	4.65
Forfeited (in dollars per share) | $ / shares	5.52
Ending Balance (in dollars per share) | $ / shares	$ 2.72

XML

Stock-based Compensation - Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 537	$ 663	$ 1,618	$ 1,539
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	61	119	202	310
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	90	74	273	184
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 386	$ 470	$ 1,143	$ 1,045

XML

Commitments and Contingencies (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) license_agreement	Dec. 31, 2021 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments due by period	$ 50
Payment period for purchase obligations	1 year
Contractual obligation	$ 3,203	$ 1,446
Lease executed but not yet commenced	$ 1,579
Term of leases not yet commenced	49 months
Royalty Agreement Terms
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of license agreements | license_agreement	2
Royalty Agreement Terms | Net sales
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	1.00%
Royalty Agreement Terms | License fees
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	21.00%

XML

Net Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss applicable to common stockholders, basic and diluted	$ (4,304)	$ (1,958)	$ (11,902)	$ (6,901)
Adjustment for gain on revaluation of warrant liabilities	0	(158)	0	(643)
Net loss applicable to common stockholders, diluted	$ (4,304)	$ (2,116)	$ (11,902)	$ (7,544)
Denominator:
Weighted-average number of shares, basic (in shares)	13,071	12,661	12,896	12,029
Effect of dilutive warrants (in shares)	0	49	0	104
Weighted-average number of shares, diluted (in shares)	13,071	12,710	12,896	12,133
Net loss per share, basic (in dollar per shares)	$ (0.33)	$ (0.15)	$ (0.92)	$ (0.57)
Net loss per share, diluted (in dollars per share)	$ (0.33)	$ (0.17)	$ (0.92)	$ (0.62)

XML

Net Loss Per Share - Antidilutive Shares (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,460	2,142	2,460	1,976
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	271	499	271	499
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	949	596	949	596
Warrants for common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	1,240	1,047	1,240	881

XML

Segment Disclosures - Operating Segments (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			2
Segment Reporting Information [Line Items]
Revenue	$ 3,329	$ 3,049	$ 9,361	$ 7,170
Cost of revenue	1,643	1,242	4,825	2,836
Gross profit	1,686	1,807	$ 4,536	4,334
Number of reportable segments | segment			2
EksoHealth
Segment Reporting Information [Line Items]
Revenue	3,224	2,716	$ 8,333	6,306
Cost of revenue	1,524	1,044	4,170	2,326
Gross profit	1,700	1,672	4,163	3,980
EksoWorks
Segment Reporting Information [Line Items]
Revenue	105	333	1,028	864
Cost of revenue	119	198	655	510
Gross profit	$ (14)	$ 135	$ 373	$ 354

XML

Segment Disclosures - Geographical Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 3,329	$ 3,049	$ 9,361	$ 7,170
Americas
Segment Reporting Information [Line Items]
Revenue	1,548	1,802	5,138	4,019
United States
Segment Reporting Information [Line Items]
Revenue	1,475	1,777	4,889	3,914
Other
Segment Reporting Information [Line Items]
Revenue	73	25	249	105
EMEA
Segment Reporting Information [Line Items]
Revenue	1,058	828	2,408	2,322
Germany
Segment Reporting Information [Line Items]
Revenue	237	313	487	845
Romania
Segment Reporting Information [Line Items]
Revenue	449	121	449	121
Other
Segment Reporting Information [Line Items]
Revenue	372	394	1,472	1,356
APAC
Segment Reporting Information [Line Items]
Revenue	723	419	1,815	829
Indonesia
Segment Reporting Information [Line Items]
Revenue	668	0	668	0
Other
Segment Reporting Information [Line Items]
Revenue	$ 55	$ 419	$ 1,147	$ 829